The role of MUC1 splice variants in dry eye and inflammation. by Imbert-Fernandez, Yoannis
University of Louisville 
ThinkIR: The University of Louisville's Institutional Repository 
Electronic Theses and Dissertations 
12-2010 
The role of MUC1 splice variants in dry eye and inflammation. 
Yoannis Imbert-Fernandez 
University of Louisville 
Follow this and additional works at: https://ir.library.louisville.edu/etd 
Recommended Citation 
Imbert-Fernandez, Yoannis, "The role of MUC1 splice variants in dry eye and inflammation." (2010). 
Electronic Theses and Dissertations. Paper 659. 
https://doi.org/10.18297/etd/659 
This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's 
Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized 
administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of the 
author, who has retained all other copyrights. For more information, please contact thinkir@louisville.edu. 
THE ROLE OF MUCI SPLICE VARIANTS IN DRY EYE AND INFLAMMATION 
By 
Yoannis Imbert-Femandez 
B.S., University of Havana, 1998 
M.S., University of Louisville, 2008 
A Dissertation 
Submitted to the Graduate Faculty of the 
School of Medicine of the University of Louisville 
in Partial Fulfillment of the Requirements 
for the Degree of 
Doctor of Philosophy 
Department of Biochemistry and Molecular Biology 
University of Louisville, School of Medicine 
Louisville, KY 
December 2010 
Copyright 2010 by Yoannis Imbert-Femandez 
All rights reserved 

THE ROLE OF MUCI SPLICE VARIANTS IN DRY EYE AND INFLAMMATION 
By 
Yoannis Imbert-Femandez 
B.S., University of Havana, 1998 
M.S., University of Louisville, 2008 
A Dissertation Approved on 
November 11,2010 
by the following Thesis Committee: 
Dr. Clfolyn M. KliQie (Mentor) 
Dr. William,w. y'~g' 
Dr. Blfbara i. Ciark 
Dr. Marcia ii7m'iIblatt 
Dr. Jill Suttles 
(15r. George N. Hajisheniallis 
Dr. Mark D. Brennan 
II 
DEDICATION 
This dissertation is dedicated to my parents for their unconditional love and 
support; also to my husband and best friend, Ernest Fernandez, without whose love, 
encouragement, and support, I would not have finished this thesis. Furthermore, this 
thesis goes to my daughter Veronica and my son Reynold, for giving me so much 
strength and making me a better person. Last, but not least, this dissertation is also 
dedicated to my sister Y oania Cannon for the love and trust she has always given me. 
III 
ACKNOWLEDGMENTS 
I would like to express my sincerest gratitude to my mentor, Dr. Carolyn M. 
Klinge, for her support, guidance, and dedication. Her vast knowledge and expertise has 
been invaluable for my scientific growth. I am heartily thankful to my former mentor, 
Dr. William W. Young, for his encouragement, support, and patience. He provided me 
with direction and became my source of inspiration. I would also like to thank the rest of 
my committee members, Dr. Marcia M. Jumblatt, Dr. Barbara 1. Clark, Dr. Jill Suttles, 
Dr. Mark D. Brennan, and Dr. George N. Hajishengallis for their assistance and 
comments. Special thanks go to my laboratory colleagues for their support over the 
years. 
iv 
ABSTRACT 
THE ROLE OF MUCI SPLICE VARIANTS IN DRY EYE DISEASE AND 
INFLAMMATION 
Yoannis Imbert-Fernandez 
November 11,2010 
Mucin 1 (MUCI) is a plasma membrane-bound glycoprotein that plays a protective role 
in corneal epithelial cells. Two full-length splice variants of MUCl: MUClIB and 
MUClIA, that differ by the inclusion of 27 bp from intron 1 and a SNP in MUClIA, but 
have identical C-terminal cytoplasmic domain (CD) sequences, were identified in human 
conjunctival tissue. I tested the hypothesis that MUCI splice variants are key immuno-
regulators that act on the ocular surface to protect the ocular surface from inflammation 
and that their expression correlates with dry eye status. The expression of MUC 11 A and 
MUClIB splice variant was examined in non-Sjogren's aqueous deficient and 
evaporative dry eye patients and compared to normal controls. The frequency of 
MUCI/A gene expression was lower in patients with non-Sjogren's aqueous deficient dry 
eye compared to controls, indicating a link between MUC 11 A and the symptoms 
associated with dry eye disease. Overexpression of MUCI/A and MUCI/B in COS-7 
cells resulted in equal protein expression and plasma membrane localization. MUClIB 
and MUClIA splice variants differed in their ability to modulate the TNFa-induced 
inflammatory responses. The MUClIB splice variant, and not MUClIA, inhibited the 
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induction ofIL-l~ and IL-8 expression by TNFa at 4 h. In contrast, MUCIIA stimulated 
TNFa-driven IL-8 mRNA and protein expression after 24 h of treatment. MUCIIB, but 
not MUCIIA, inhibited TNFa-induced luciferase activity from an NF-KB reporter. Both 
MUCIIB and MUClIA blocked the induction of miR-21 by TNFa. In addition, 
MUCIIA, but not MUClIB, increased basal expressIOn of TGF~. These data 
demonstrate for the first time that MUClIA and MUCIIB are genetic susceptibility 
factors with different anti-inflammatory activities. 
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CHAPTER 1- INTRODUCTION TO DRY EYE DISEASE 
The Definition and Classification of Dry Eye Disease 
Dry eye disease or keratoconjunctivitis sicca (KeS) is a common disorder of the 
tear film and ocular surface, affecting more than 10 million people in this country (1). 
Dry eye is one the most common diseases seen in the ophthalmologic clinic, and it is 
significantly more prevalent among women than men (2). Whereas dry eye is not 
typically a sight-threatening disease, it is characterized by symptoms of irritation and 
discomfort and therefore it decreases the patient quality of life considerably (3). 
For many years, dry eye was defined as a disorder of the tear film due to tear 
deficiency or excessive tear evaporation that results in inflammation and epithelial 
damage (4). This definition, however, was vague and did not include the word "disease" 
which could be interpreted as if dry eye syndrome was not a real disease but a 
disturbance. The dry eye workshop (DEWS) reviewed and broadened the definition and 
classification of dry eye in 2007. The new definition is as follows: "Dry eye is a 
multifactorial disease of the tears and ocular surface that results in symptoms of 
discomfort, visual disturbance, and tear film instability with potential damage to the 
ocular surface. It is accompanied by increased osmolarity of the tear film and 
inflammation of the ocular surface" (5). This new definition incorporates the concept of 
a "core mechanism" driven by tear hyperosmolarity and tear film instability that causes 
damage to the surface epithelium and triggers inflammation (6). 
The tear film is responsible for lubricating, nourishing and protecting the ocular 
surface and is composed of secretions from three major sources: the lacrimal glands 
which secrete the aqueous tear fluid and a number of associated proteins; the meibomian 
glands which secrete lipids that retard evaporation from the ocular surface; and 
conjunctival goblet cells and non-goblet conjunctival epithelial cells that secrete mucins 
that contribute to the viscoelastic properties of the tear film (7;8). Deficiency in any of 
the tear film components can contribute to the pathology of dry eye disease (7). 
Based on etiology, dry eye disease has been classified into two major categories: 
aqueous tear-deficient and evaporative dry eye (5). Aqueous tear-deficient dry eye, as 
the name denotes, is characterized by a decrease in tears due to a failure of tear secretion 
by the lacrimal glands (9). Aqueous tear-deficient dry eye is subdivided into two 
categories: Sjogren's aqueous deficient and non-Sjogren's aqueous deficient. Sjogren's 
aqueous deficient is a chronic autoimmune disease in which the lacrimal and salivary 
glands are targeted by an autoimmune process leading to cell death (10). As a 
consequence hyposecretion of the tears and saliva is observed in these patients. In 
contrast, evaporative dry eye is characterized by normal lacrimal gland function and 
excessive water loss from the ocular surface. Evaporative dry eye is commonly 
associated with abnormal lipid composition of the tears due to meibomian gland 
dysfunction (9; 11; 12). 
The Lacrimal Functional Unit (LFU) 
In the light of new knowledge, dry eye disease is recognized as a disturbance of 
the "Lacrimal Functional Unit (LFU)" and not just a problem of the tear film and the 
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lacrimal gland (6). The LFU is an integrated system that is composed of the lacrimal 
glands, the ocular surface (conjunctiva, cornea and meibomian glands), the eyelids and 
the sensory and motors nerves that connect them (5). This functional unit controls the 
dynamics of the tear film in response to environmental, endocrine, and cortical signals. 
The overall function of the LFU is "to maintain the integrity of the tear film, the 
transparency of the cornea and the quality of the image displayed onto the retina" (5). 
Consequently, damage to any of the components of the LFU will alter the system 
homeostasis resulting in abnormal tear film and hence dry eye disease. Changes in the 
tear composition and stability due to dysfunction of the LFU leads to tear 
hyperosmolarity, tear instability and ocular surface inflammation which are considered 
the core mechanisms in the etiology of all subtypes of dry eye disease (5). 
Increased tear osmolarity was first reported decades ago (13), and it IS now 
recognized as the central mechanism triggering surface inflammation, damage and 
symptoms of discomfort. Tear hyperosmolarity is a consequence of either low aqueous 
tear flow and/or excessive evaporation. In some forms of dry eye, tear film stability is 
the initiating event rather than tear hyperosmoloratity (14). Both tear hyperosmolarity 
and tear film instability are shown in Figure 1 as the initiators of a cascade of 
inflammatory responses mediated via activation of mitogen-activated protein kinase 
(MAPK) and nuclear factor-kappaB (NF-KB) pathways. These inflammatory events in 
tum lead to progressive cell death, as has been demonstrated for goblet cells (15). Goblet 
cell loss and the subsequent decrease in the mucin MUC5AC, is observed in every form 
of dry eye (16; 17), and it feeds back into the cycle. As dry eye disease progresses, other 
factors can enter the cycle and further amplify these initiating events. 
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Figure 1. The core mechanisms causing dry eye disease. Adapted from the 2007 
Report of the International DEWS. The figure shows the inter-connection of events 
occurring in dry eye that are driven by tear hyperosmolarity and tear film instability. 
Tear hyperosmolarity caused by reduced tear flow and/or decreased tear evaporation 
induces the activation of an inflammatory signaling cascade at the ocular surface that 
results in the release of inflammatory mediators into the tears. Cellular damage triggers 
cell death by apoptosis, loss of goblet cells, and disturbance of mucin expression, leading 
to tear film instability. This instability increases even further the ocular surface 
hyperosmolarity and closes the vicious circle. Tear film instability can also be initiated as 
an independent event of tear hyperosmolarity. Factors that contribute to tear film 
instability include ocular allergy, topical preservative use, and contact lens (CL) wear. 
The epithelial damage caused by dry eye stimulates corneal nerve endings, leading to 
symptoms of discomfort and eventually to inflammation of the lacrimal gland. 
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Dry Eye and Inflammation 
Chronic inflammation is a common denominator in all forms of dry eye disease, 
and immunosuppressive drugs such as cyclosporine and steroids have been reported to 
improve symptoms and signs of dry eye (18). Both cellular and soluble mediators have 
been demonstrated to playa role in the ocular surface inflammation that develops during 
the course of dry eye. 
The exact mechanisms responsible for the development of ocular surface 
inflammation in dry eye have not been firmly established. However, extensive evidence 
supports the idea that inflammation is initiated by a stress response of the surface 
epithelial cells to increased tear osmolarity and/or desiccation. Tear hyperosmolarity 
stress in tum, activates a variety of signaling pathways, including MAPK pathways, in 
particular p38 and c-Jun N-terminal kinases (JNK), and NF-KB in the ocular surface 
epithelia (19;20). These activated kinases are responsible for the regulation of a wide 
number of genes involved in the inflammatory response. Pro-inflammatory cytokines, 
e.g., interleukin-l beta (IL-l ~), tumor necrosis factor alpha (TNF a), IL-8, and matrix 
metalloproteinases (MMPs) are among the inflammatory mediators elevated during the 
inflammatory response by the corneal epithelium (21-24). In addition, increased 
expression of immune activation molecules including intracellular adhesion molecule 1 
(ICAM-I) and HLA-DR has been reported in both Sjogren's and non-Sjogren's aqueous 
deficient dry eye (25;26). Cytokines released from activated epithelial cells cause 
lymphocytic infiltration and increased apoptosis of epithelial-secreting cells (27), 
subsequently leading to a cycle of chronic inflammation and ocular surface injury. For 
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that reason inflammation is seen as both the cause and the consequence of cell damage 
accompanying dry eye. 
Animals Models of Dry Eye Disease 
In an effort to understand the causative mechanisms leading to the pathogenesis of 
dry eye several animal models have been generated. These animal models have provided 
important clues in identifying the underlying molecular pathways contributing to the 
development of dry eye disease. 
Although dogs can spontaneously develop dry eye disease and therefore would 
seem to be ideal to study the development and progression of dry eye, this animal model 
is limited for two primary reasons: 1) canine dry eye is a naturally-occurring (low 
frequency) disease and thus, it is difficult to generate enough dogs with dry eye to 
conduct experiments; 2) dogs are people's beloved pets. Rabbits, rats and mice are the 
preferred animal models of dry eye disease. The current animal models are generated by: 
1) inducing lacrimal insufficiency, which mimics Sjogren's dry eye; 2) removal or 
obstruction of the lacrimal or meibomian glands; 3) mechanical damage, i.e., inserting a 
lid specula for a period of time to prevent blinking; and 4) blockage of neuronal 
stimulation for tear secretion, e.g., using scopolamine which blocks the cholinergic 
receptors in the lacrimal gland and results in decreased aqueous production (reviewed in 
(28)). 
Due to the availability of several knockout and transgenic mIce that mimic 
autoimmune disorders, the mouse model has become the preferred model to study 
Sjogren's syndrome (29). The nonobese diabetic (NOD) mouse model has been 
6 
extensively used to study Sjogren's syndrome (30). These mice show infiltration of 
CD4+ Th1 cells in the lacrimal glands and submandibular glands. Although one 
limitation of this model is the fact that the tear secretion is only reduced by 30% 
compared to the wild-type animals, the NOD mice is one of the only two models that 
show any decrease in tear secretion (31). The transforming growth factor P (TGFP) 
knockout mouse is another model of lacrimal gland inflammation. These mice develop 
"crusty eyes" that eventually close as the disease progresses (32), the presence of 
lymphocytes in the lacrimal glands has been confirmed in these animals. Unfortunately, 
although TGFp knock-out mice is a good model to study Sjogren's syndrome, these 
animals have a very short lifespan, i.e., they die between 3 and 4 weeks post-natal, which 
greatly limits their use. In addition, these mice develop inflammation in several vital 
organs which in tum compromise dry eye study (29;32). 
There is no doubt that environmental conditions play an important role in the 
development of dry eye. There are several animal models of dry eye generated by 
subjecting mice to continuous air flow exposure or keeping the mice in air controlled 
chambers to mimic environmental stress conditions (29). 
In summary, the currently available animal models of dry eye mirror different 
subtypes of dry eye disease. However, because of the multi-factorial nature of dry eye 
disease, has it has been difficult to incorporate all the complexity of this chronic disease 
in a single animal model. 
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Etiology and Risk Factors for Dry Eye Disease 
As indicated above, the causes of dry eye are obscure, but established risk factors 
for dry eye disease include female sex, older age, postmenopausal hormone replacement 
therapy (HRT) (33), a diet low in omega-3 fatty acids (34), and vitamin A deficiency 
(35). 
The role of sex hormones in ocular surface homeostasis has been recognized and 
the underlying mechanism(s) by which hormonal status may contribute to dry eye is 
currently being investigated. It was initially hypothesized that estrogens were the key 
hormone protecting against dry eye disease. However, the role of estrogens in protecting 
against dry eye was questioned after studies demonstrated that women who use HR Tare 
at increased risk of dry eye disease (33). Instead, androgen deficiency may be the critical 
etiologic factor in the pathogenesis of aqueous-deficient and evaporative dry eye disease 
during menopause. Androgen levels decrease in post-menopausal women (I), and 
androgen deficiency has been correlated with dry eye in androgen insufficiency 
syndrome (36) and anti-androgen medication treatment (37). Androgens have been 
shown to playa crucial role in maintaining an anti-inflammatory state of the LFU by 
constitutively suppressing inflammation of the lacrimal gland. Androgens inhibit 
lacrimal gland inflammation by up-regulating the anti-inflammatory cytokine TGFI3 (38). 
In addition, androgens increase the secretion of the meibomian glands which produce the 
lipids found in the tear film (39). The complex role of sex hormones in ocular surface 
health needs further study. 
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Therapies for the Treatment of Dry Eye 
There has been progress in our understanding of the pathophysiology of dry eye 
that has allowed a shift in dry eye management from simply lubricating and hydrating the 
ocular surface to treatments that stimulate natural production of tears, maintain ocular 
surface epithelial barrier function, and inhibit inflammation at the ocular surface. Current 
therapies for patients with dry eye disease include the use of lubricants, tear stimulants, 
tear retention procedures, anti-inflammatory therapies and biological tear substitutes (5). 
These therapies are designed to improve the patient's ocular comfort and quality of life 
but do not yet eliminate the underlying pathology of the disease since the precise etiology 
of dry eye remains unknown and is likely multi-factorial. It is possible that future 
therapies will focus on replacing or providing specific tear components that have an 
important role in maintaining ocular surface integrity. Further research will be needed to 
identify these key factors and to provide better diagnostic tools to measure their 
concentrations in tears. 
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CHAPTER 11- SIGNIFICANCE OF MUCI IN DRY EYE DISEASE 
Introduction to Mucins 
Mucins are high molecular weight O-glycosylated proteins localized on the apical 
border of epithelial cells (40) including the ocular surface as well as the respiratory and 
intestinal tracts (41). Mucins play a central role in the protection, lubrication and 
hydration of epithelial surfaces. The overall function of mucins is to help preserve the 
integrity of surfaces that are constantly exposed to foreign substances and pathogens. In 
recent years it has become clear that the functions of mucins are more complex than 
simply forming a protective barrier. The structure and localization of mucins enables 
them to play important roles in processes including cell-cell communication, cell-
extracellular matrix interactions, and intracellular signaling. It is well established that 
mucins are important for the maintenance of a healthy ocular surface (42), as highlighted 
by the finding of several examples of mucin alterations in dry eye disease (16;43;44). 
At present, at least 20 mucins are members of the human MUC gene family (45). 
They are named MUCs 1, 2, 3, etc., according to the order in which they were 
characterized. Mucins are subclassified into two classes: soluble, gel-forming mucins 
and membrane-tethered mucins. The major ocular mucins are expressed differently by 
the ocular surface cells, i.e. soluble mucins are expressed exclusively by conjunctival 
goblet cells and membrane-tethered mucins are expressed mainly by non-goblet epithelia 
(reviewed in (42;46)). 
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One common feature in all mucins is the presence of a variable number of tandem 
repeats (VNTR) in the extracelullar domain: the "mucin domain" (for a review see 
(41;47)). The VNTR contains multiple serine and threonine residues that serve as 0-
glycosylation sites. The extensive O-glycosylation of the VNTR accounts for ~ 50-80% 
of the mucin mass (47). Moreover, the type and extent of mucin glycosylation accounts 
for the biochemical and biophysical properties of each mucin. Based on their 
glycosylation status, mucins regulate important cellular processes including cell 
adhesion, cell-cell interaction, and immunological responses (48-50). Another important 
characteristic of the mucins is the presence of cysteine-rich regions in the N- and C-
terminal domains. These cysteine-rich regions allow disulfide bond formation resulting 
in huge multimers that assemble to form mucus in the gastrointestinal and respiratory 
tracts (51). 
In recent years, the membrane-bound mucins have received increased attention 
for their role in regulating intracellular signaling. Membrane-bound mucins have a 
relatively short cytoplasmic domain (CD) that acts as a docking site for components of 
several cytoplasmic signaling pathways thereby providing signals in response to 
alterations in the local environment (52). Among the membrane-tethered mucins, MUC1 
is the best characterized with regard to cell signaling. 
MUCI 
MUC1, also designated MUCIIREP or MUCIIB, was the first cloned 
transmembrane mucin and is expressed at the ocular surface (44). Structurally, MUC1 
contains two domains of functional significance (Fig. 2); 1) the >250 kDa N-terminal 
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extracellular domain (MUCI-N) which contains the 20 aa VNTR that are extensively 0-
glycosylated (53) and 2) the ~25kDa C-terminal domain (MUCI-CD) which includes a 
58 aa extracellular domain, a 28 aa transmembrane domain, and a 72 aa cytoplasmic tail 
(MUCl.CT) that is highly conserved across species (54). The VNTR is the largest 
domain of MUCI and does not share significant homology with other mucin genes (55). 
The MUCI protein is translated as a single polypeptide; however, as a result of an 
autoproteolytic event in the endoplasmic reticulum, the MUCl-N and MUCI-CD 
subunits are generated (56). The MUCI-N and MUCI-CD domains remain tightly 
associated at the plasma membrane through non-covalent interactions. On normal 
epithelial cells, the MUC 1 heterodimer localizes at the apical border (40). However, in 
carcinoma cells that have lost polarity, MUCI is highly overexpressed and its localization 
is no longer restricted to the apical border, thus allowing it to interact with adjacent 
proteins which impacts the cell biology and survival of tumor cells. 
MUCI is overexpressed in > 90% of breast tumors and also in most types of 
ovanan, lung, colon and pancreatic carcinomas, as well as in inflammatory diseases 
(55;57). MUCI has long been known as a tumor associated protein and its expression 
has been linked to enhanced cell growth, tumorigenicity, metastasis, and inhibition of 
oxidative stress-induced apoptosis (58). These oncogenic effects are attributed to the 
interaction between the MUC 1 CD and signaling molecules including epidermal growth 
factor (EGFR), ~-catenin, p53, and estrogen receptor a (ERa.) [reviewed in (58;59)]. 
Recent work by Kufe's group demonstrates that MUCI-CD accumulates in the cytoplasm 
as oligomers that trans locate into the nucleus by a mechanism involving importin ~ and 
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Figure 2. Schematic representation of the MUCI protein. Autoproteolytic cleavage 
yields the two subunits ofMUCl : the MUCI-N terminal domain (MUCI-N) and the C-
terminal domain (MUCI-CD). The MUCI-N extracellular subunit contains ~40-80 
tandem repeats of 20 aa (shown as TR) that are O-glycosylated. The MUCI-CD consists 
of a short extracellular region (58 aa), a transmembrane domain (TM, 28 aa), and the 
cytoplasmic tail (CT) composed of 72 aa (also known as MUCl.CT). The sequence of 
the CT is depicted at the bottom of the figure and some of the MUCI interacting proteins 
are shown. 
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nucleoporin p62 (60). As shown in Fig. 2, MUCI is palmitoylated at the CQC motif. 
MUC 1 palmitoylation regulates its recycling without affecting endocytosis (61). 
The Role of MUCI in the Regulation of Cell Signaling 
Regulation of cell signaling by MUCI occurs when the MUCI-CD associates 
with signal transduction mediators that include ~-catenin, p53, inhibitors of IKB kinase 
(IKK), and ERa. As a result of this association MUCI-CD can translocate to the nucleus 
and regulate target gene transcription (57). MUC 1 also regulates extracellular signaling 
by the interaction of intercellular adhesion molecule 1 (ICAM-I) as a ligand for MUCI 
that initiates a calcium signaling response which leads to reorganization of the 
cytoskeleton and increased cell migration (62-64). It has been demonstrated that binding 
to Pseudomonas aeruginosa, or its flagellin protein, promotes phosphorylation of serine 
residues on the MUCI-CD leading to the activation of the ERK pathway. 
Of special interest to the research described in this dissertation is the role of 
MUCI in regulating inflammatory responses. MUCI gene ablation experiments in mice 
resulted in increased inflammatory responses in the airways and a predisposition to 
develop conjunctivitis indicating an anti-inflammatory role of MUCI (65;66). For 
example, in one study using a model of bacterial lung infection, the lungs in the Muc 1-1-
mice showed decreased colonization of P.aeruginosa (65). Higher levels of tumor 
necrosis factor alpha (TNFa) and interleukin 8 (IL-8), proinflammatory mediators were 
detected in bronchoalveolar lavage fluid of the Muc 1-1- mice compared to wild-type 
littermates (65). Similar findings were reported in primary human bronchial epithelial 
cells where RNAi knockdown of MUCI expressed resulted in an increase in flagellin-
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induced- IL-8 production (65). It was recently reported that MUCl can inhibit the 
activation of Toll-like receptors (67). In addition, MUCl expression in resting T 
lymphocytes can inhibit the activation of T cells (68). Taken together, these results 
suggest that MUCI acts as an anti-inflammatory agent which is relevant to the 
pathogenesis of dry eye. In contrast to these reports, there is recent evidence that MUCI 
can activate the NF-Kl3 pathway in human cancer cell lines including MCF-7 and HeLa 
cells as well as in normal mammary epithelial cells (MCF-lOA) (69), indicating a 
possible pro-inflammatory role of MUCI. Therefore, the role ofMUCI in inflammation 
is controversial and requires further investigation. 
Regulation of MUCI Gene Expression 
Given the importance of MUCI in maintaining cellular homeostasis, it is critical 
to understand how MUCI expression is regulated. In humans, the MUCI gene spans 4 to 
7 kb on chromosome 1 q21-24. Studies of the MUC 1 promoter revealed the location of 
the typical TAT A box 25 nucleotides upstream of the transcriptional start site (70;71). 
Numerous binding sites for transcriptional regulators are present in the promoter of 
MUC I, including specificity protein-l (Sp 1), activator protein I (AP-I), nuclear factor 1 
(NF-l), NF-KB, ER, and Signal Transducers and Activators of Transcription (STAT) 
transcription factors (70-72). 
Many of the regulatory elements in the MUC 1 promoter have been functionally 
characterized. The region containing the Sp 1 cis-element was shown to be important to 
drive transcriptional activity of a reporter gene in MUCI-expressing epithelial cell lines 
(73). The STAT binding element in the MUCI gene mediates the interferon y 
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(IFNy)- driven upregulation of MUCI (72;74). Moreover, STAT3 has been shown to 
bind to the MUCI promoter in response to interleukin 6 (IL-6) in human mammary 
epithelial cells (72). MUCI is upregulated in response to TNFa treatment via NF-KB 
activation and binding to the -589/-580 element (74). The regulation of MUCI by 
progesterone (PR) has been reported, and multiple putative estrogen and PR response 
elements have been identified in the human MUCI promoter (71). In mice, Muc1 
expression has been shown to be regulated by both progesterone and 17~-estradiol (E2) 
(75;76), with E2 specifically stimulating Muc1 expression in the uterus. However, direct 
binding of ERa, ER~, PR-A or PR-B to the Muc1 promoter has not been demonstrated 
(77). Therefore, further studies will be necessary to elucidate the role of hormones in the 
regulation of MUCI gene expression. At the post-translational level, MUCI is been 
shown to be downregulated by microRNA miR-125b (78). 
Splice Variants ofMUCl 
MUCI pre-mRNA undergoes alternative splicing generating several different 
variants, with at least twelve splice variants having been described to date (79). Thus far, 
no functional differences have been attributed to any individual splice variant. Early 
work by Hilken's group revealed that the alternative retention of 27 bp from the intron at 
the start of ex on 2 gives rise to the MUCIIA splice variant (Fig. 3) (80). The selection of 
splice variant MUCIIA or MUClIB is controlled by a G to A single nucleotide 
polymorphism (SNP) (rs4072037) that is located 8 nucleotides downstream from the start 
of exon 2 of MUCl. The presence of G at the rs4072037 SNP generates the MUCIIA 
splice variant, whereas having A at the SNP site gives rise to the MUClIB form. In 
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Figure 3. Schematic representation of the MUClIA and MUClIB splice variants. 
The upper panel shows the MUCI /A and MUCIIB isoforms at the DNA level. Each box 
represents an exon for a total of9 exons. MUClIA and MUCIIB differ by the insertion of 
27 nucleotides between exons 1 and 2. The SNP present in exon 2 determines the choice 
of splicing. The regions containing the sequences for the signal peptide, VNTR, and 
transmembrane domain (TM) are shown in between the two variants. The lower panel is 
a representation of the protein resulting from MUClIA and MUClIB splice variants. The 
additional 9 aa resulting from the 27 nucleotide insertion is shown in blue in the 
extracellular domain ofMUClIA. 
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addition to the MUCI/A and MUClIB splicing choice, the SNP rs4072037 has also been 
associated with the length of the VNTR (80;81) although this association does not occur 
in 100 % of the cases (44). Specifically, the G allele (MUClIA) is correlated with larger 
size VNTRs and A allele (MUCl/B) is associated with smaller size VNTR. According to 
the Ensembl database, the frequencies of the GG, G/A and AA genotypes in the 
Caucasian population are 18, 49 and 33 %, respectively 
As compared to MUClIB, the MUCI/A protein contains an extra stretch of 9 aa 
that are located on the amino terminal side of the tandem repeat region (Fig. 3). Whether 
these additional 9 aa in MUCI/A affect MUCI function is unknown; however, analysis 
of the MUClIA protein sequence predicts a change in the signal peptide cleavage site 
(82;83) which can potentially affect the protein trafficking and localization. 
In addition to MUClIA and MUClIB splice variants, MUCI transcripts that have 
lost the tandem repeat region (MUClIY, MUClIYalt and MUClIZ(X)) or transcripts 
lacking the transmembrane domain (MUC lISEC) have also been described (84-86). As 
part of my dissertation research described in Chapter III, the expression of six MUCI 
variants in human ocular surface tissues was reported (79). 
Dissertation Specific Aims and Hypotheses 
As reviewed in Chapter I, dry eye disease is a complex set of diseases of unknown 
cause that affects at least 10 million people in the u.S. (87). At present, there are no 
biochemical markers that can predict a patient's susceptibility to dry eye disease. The 
current therapies against dry eye disease are directed at alleviating the symptoms rather 
than eliminating the problem. Therefore, uncovering possible genetic susceptibility 
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factors may lead to a better diagnosis as well as novel and personalized therapies that will 
improve or even eliminate dry eye disease. MUCI plays an important role in protecting 
the ocular surface by sensing the surrounding environment, preventing the adhesion and 
access of foreign molecules onto ocular surface epithelia, and possibly by regulating 
inflammation (88). My initial results shown in Chapter III indicated that MUCI splice 
variants may be differentially expressed in dry eye patients compared to normal controls. 
This striking pattern prompted me to focus my dissertation research on the role ofMUCI 
splice variants as susceptibility factors involved in the development of dry eye. My 
working model is that MUCIIA and MUClIB splice variants are genetic predisposing 
factors for the development of dry eye, although they are not sufficient to cause disease 
(Fig. 4). Chapters III and IV summarize the research that links MUCIIA and MUClIB 
expression to the development of dry eye disease. The expression of MUCIIA or 
MUClIB at the ocular surface will either protect or enhance, respectively, the ocular 
surface damage after the patient encounters a second "hit". It is very likely that one 
mechanism by which MUCI splice variants are involved in dry eye development is by 
regulating inflammatory responses differently; therefore, in Chapter V, experiments that 
test that possibility are described. The long term goal of the studies described in this 
dissertation was to elucidate the molecular mechanisms involved in the pathogenesis of 
dry eye disease and to ascertain how MUCI splice variants contribute to the symptoms 
and pathology of dry eye disease. I tested the hypothesis that MUC I splice variants are 
key immuno-regulators that act on the ocular surface to protect the ocular surface from 
inflammation and that their expression correlates with dry eye status. 
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The specific aims of this dissertation were: 
Aim 1: To determine the frequencies of individuals expressing MUClIA only, 
MUClIB only, and MUClIA-MUClIB in patients diagnosed with 
evaporative dry eye, non-Sjogren's aqueous deficient dry eye, and 
control volunteers. 
Aim 2: Determine whether MUCI/A and MUClIB splicing variants differentially 
modulate inflammatory responses. 
Aim 3: Elucidate the molecular mechanisms through which MUCI splice variants 
regulate inflammatory responses. 
It is important to note here that these aims were modified from my Exam lIB. 
Aim 2 of this proposal corresponds to Aim 4 of my Exam lIB. Aim 3 was not on the 
original proposal. Aim 3 evolved from the results that I obtained while addressing Aim 
2. On February 13, 2008, I defended my Exam lIB dissertation proposal and I was 
advised to prioritize experiments for Aim 4. Because the cloning of MUCIIA took 
longer than anticipated, I did not have time to address Aims 2 and 3. However, I 
generated some preliminary data that is included as "Appendix I" in this dissertation. 
The aims that were not addressed in this dissertation are shown below. 
Initial Aim 2: Determine if MUCI interacts directly and functionally with ERa and/or 
ERP in human submandibular gland (HSG) and ocular surface epithelial cell lines. 
Initial Aim 3: Elucidate the anti-inflammatory role ofMUCl, ERa and/or ERp in human 
submandibular gland and human ocular surface epithelial cell lines. 
20 
Genetic pre-
disposition 
Second "hit" 
I 
MUCI/A 
expression 
Normal 
+ 
MUCI/B 
expression 
Dry eye 
Figure 4. Proposed model for MUCI splice variants as key factors in the 
development of dry eye disease. MUCIIB expression correlates with non-Sj6gren's and 
evaporative dry eye disease. Thus, my research tests the hypothesis that MUClIA and 
MUCIIB are genetic factors that will either protect from (MUClIA) or contribute to 
(MUClIB) the development of dry eye. Other predisposing factors such as gender, 
hormonal status, or dry environment act in combination with the MUC 1 status to result in 
either a normal or damaged ocular surface. Other environmental exposures, e.g., 
cigarette smoke, air quality, and air pollution, may also affect dry eye disease. 
Inflammation is one of the core mechanisms causing dry eye disease, and it possible that 
MUClIA and MUClIB can differentially regulate the inflammatory response. 
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CHAPTER 111- MUCl SPLICE VARIANTS IN HUMAN OCULAR SURFACE 
TISSUES: POSSIBLE DIFFERENCES BETWEEN DRY EYE PATIENTS AND 
NORMAL CONTROLS 
The text of this chapter was published in Exp. Eye Research; 83(3):493-501 (2006) 
Introduction 
The nonnal human tear film lubricates and protects the ocular surface against 
pathogens and environmental challenges. Mucins are large, highly O-glycosylated 
proteins that function at the ocular surface to facilitate lubrication, retain water, and 
provide a barrier against pathogen invasion (42;46). Many of the viscoelastic properties 
of mucins are provided by the large amount of carbohydrate found on mucins. One of the 
transmembrane mucins, MUC1, is present on corneal and conjunctival epithelial cells 
(89) and in the tears (90). The majority of the O-glycosylation sites ofMUCI are present 
in a highly polymorphic core region containing a variable number of tandem repeats 
(VNTR). Each repeat of 20 amino acids bears 5 potential sites for O-glycosylation. 
MUCI alleles can be divided into size classes that contain small (30-45) or large (60-90) 
numbers of repeats. 
Alternative splicing generates multiple fonns of mRNA from a single pre-mRNA 
and is a major mechanism for generating proteome complexity (91 ;92). At least twelve 
splice variants of MUCI have been described in human tumor tissue (Fig. 5). These 
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Figure 5. MUCI splice variants. The exon-intron pattern is from the Ensembl website 
(http://www.ensemb1.org). Variants are from the following references: MUCIIB (53 ;82) 
and MUCliA (82;83); MUCI Y (86); MUClIZ(X) (93 ;94); MUC liSEC (83); 
MUC lICT80 and MUC lICT58 (95); and MUC lIZD (84). MUCIN! has not been 
described previously; it contains 99 bp from the 5' end of the first intron and 27 bp from 
the 3' end of that intron. SP, signal peptide; SNP rs40n037 at position 8 of exon 2; TR, 
tandem repeat; and TM, transmembrane domain. The TR is not drawn to scale due to its 
large and variable size. MUCI-I and MUCI-2 refer to real-time RT-PCR primer-probe 
sets. The arrows below MUC liA represent the primers used in RT-PCR to detect 
MUC liA and MUC liB (Fig. 9, panel I); the arrows below MUCI fY for the primers to 
detect MUClIY and MUClIZ(X) (Fig. 9, panel IV); the arrows below MUC liSEC for 
the primers to detect that splice variant (Fig. 9, panel III) ; the arrows below MUCl fYI for 
the primers to detect that splice variant (Fig. 9, panel II); and the arrows below 
MUC lICT80 for the primers to detect MUC lICT80 and MUC lICT58. 
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variant transcripts include four full length transcripts: MUCI/B (53;82) and MUCI/A 
(82;83) differ by the inclusion of 27 bp from intron 1 in MUC 11 A; and MUC 1ICT80 and 
MUC1ICT58 differ from MUC1IA and MUCI/B in the cytoplasmic tail region (95). The 
MUC1ISEC transcript has lost the transmembrane domain and 
therefore encodes a soluble protein product (83). The nomenclature for variant 
transcripts that lack the tandem repeat region is confusing because in addition to 
MUCIfY (86) another species was simultaneously named MUC1IZ (93) and MUC1IX 
(94). Here we refer to that variant as MUC1IZ(X). While several of these variants have 
also been found in normal human tissues, none have been reported in human ocular 
surface tissues despite the potential impact that these altered proteins could have on 
normal ocular surface physiology and ocular surface disease. The first purpose of this 
report is to characterize MUCI splice variants in normal human ocular surface tissues. 
Dry eye syndrome or keratoconjunctivitis sicca (KCS) is due to tear deficiency or 
excessive tear evaporation that causes damage to the ocular surface and symptoms of 
ocular discomfort (96). The two major types of KCS are aqueous deficient and 
evaporative. Although dry eye disease is common, the causes are obscure. Factors 
implicated in KCS pathogenesis include lacrimal inflammation, interruption of neuronal 
stimulation for tear secretion, defects in Meibomian gland function, and defects in mucin 
expression (16;43). In the present report we compared conjunctival epithelium from 
aqueous deficient dry eye patients and normal control donors for the presence ofMUCI 
splice variants. The results suggest that the percentage of dry eye patients expressing the 
MUC 11 A variant in the conjunctival epithelium is lower than in normal control donors. 
MUCI/A has been shown to be associated with alleles containing an increased number of 
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tandem repeats (80;81). Therefore, we hypothesize that one factor in susceptibility to dry 
eye disease may be reduced levels ofMUCl having larger numbers of tandem repeat and 
consequently reduced protection of the ocular surface. 
Material and Methods 
Tissues and RNA: The inclusion of human subjects was in accordance with the 
Declaration of Helsinki and was approved by the local Institutional Review Board and 
the Human Subjects Protection and Privacy Office of the University of Louisville. 
Informed Consent and Research Authorization were obtained prior to collection of 
samples from enrolled subjects. Donor corneas and conjunctivae were obtained from the 
Kentucky Lions Eye bank. Conjunctival tissue included conjunctiva from the superior 
and inferior bulbar regions and from the nasal fornix. Corneas were trimmed free of all 
scleral tissue. Both corneas and conjunctivae were homogenized in ice cold RNA lysis 
buffer (Qiagen) and eluted through QIAshredder microcolumns. Total RNA was isolated 
. RN TM· I usmg easy mlcroco umns. 
Lacrimal glands were obtained from either the National Disease Research 
Interchange (Philadelphia, PA) or from cadavers donated to the University of Louisville 
Fresh Tissue Laboratory. Glands were dissected and recovered extra-orbitally, stored in 
RNA Later (Qiagen), and processed for RNA isolation as described above. 
Brush cytology was performed using sterile dacron polyester swabs (Puritan 
Medical Products). The temporal or nasal bulbar conjunctiva was scraped by gentle 
rotation of the brush. The swab was then immersed ten times in 1.0 ml of RL T lysis 
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buffer that was then mixed, frozen on dry ice, and stored at -80°C. Samples were thawed 
at 37°C for 10 min, Vortexed for 30 sec, purified through QIA shredder columns, and 
then total RNA was obtained on RNeasy columns. Tears were collected in capillary 
tubes. 
Dry eye subjects (N = 9) were diagnosed as having moderate to severe aqueous 
deficient dry eye with tear film instability. Dry eye was documented by reduced 
Schirmer test «7 mm/5 min), reduced tearfilm breakup time «10 sec), and ocular 
surface staining (cornea with fluorescein, conjunctiva with lissamine green). There was 
no inherent mucosal disease (ocular cicatricial pemphigoid, scarring from Stevens-
Johnson syndrome, trachomatous scarring) (97). The normal subjects (N = 15) were 
without symptoms of dry eye and demonstrated on clinical examination normal tear 
volume and stability with no ocular surface staining, normal tear break up time, and 
normal Schirmer test values. No subjects had undergone LASIK surgery. 
The quality and quantity of total RNA was evaluated using the Agilent 2100 
Bioanalyzer (Agilent). 
Quantitative mRNA analysis by real-time RT-PCR: Gene expreSSIOn levels were 
determined after reverse transcription by real-time PCR using an Applied Biosystems 
PRISM 7000 or 7300 Sequence Detection System. Total RNA was treated with DNase, 
and then cDNA was synthesized using random hexamers and the SuperScript II first-
strand synthesis kit (Invitrogen). The following primer-probe sets for real-time RT-PCR 
(Taqman) analysis were obtained as Assays on Demand reagents (Applied Biosystems 
assay ID): MUCI Hs00410317 ml (assay location 100 of Genbank mRNA M32739.1 
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spanning the exon I-exon 2 boundary, see Fig. 5) referred to here as the MUCI-I set and 
HsOOl59357 ml (assay location 896 ofmRNA AY327596.1 spanning the ex on 8-exon 9 
boundary) referred to here as the MUCI-2 set; and I8S rRNA Hs9999990I_sl. 
Isoform expression values were compared to those obtained for the endogenous 
control 18S rRNA, which we used rather than GAPDH or p-actin because of the 
variability of those two latter endogenous controls between tissues and among individuals 
(98;99). Ct is defined as the threshold cycle at which the fluorescence produced by the 
cleavage of the Taqman fluorogenic probe rises above a background level. Delta Ct 
values (Ct experimental minus Ct I8S rRNA) were converted to a fold difference 
between experimental and I8S rRNA, and presented as [lI(fold difference)] x 10,000 so 
that stronger expression is represented by a higher value as previously described (100). 
Each real-time RT-PCR assay was run in duplicate or triplicate; in all cases the range of 
duplicate values was < 5% of the mean and the standard deviation of triplicate values was 
<3.5% of the mean. 
Conventional PCR and sequencing of PCR products: Primers used for conventional PCR 
were: primers PI and P2 from (101) for detection ofMUClIA and MUClIB; primers P2 
and P7 from (95) for the detection of MUCIISEC; and primers P6 and PI from (93) for 
the detection of MUClIY and MUClIZ(X); and for detection of MUCINI FWD 5'-
TCACAGTGCTTACAGGTGAGG-3' and REV 5'-ACAACTGTTGCGGGTTTAGG-3'. 
Products were analyzed on a DNA 500 chip of the Agilent 2100 Bioanalyzer. PCR 
products of MUCIIA and MUClIB amplification also were digested with AlwNI (New 
England Biolabs) and analyzed on a DNA 500 chip. For sequencing the PCR products 
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were ligated into pGEM-T (Promega), and the plasmids were transformed into E. coli 
DH5a (Invitrogen). DNA sequencing was performed in the EpScor sequencing facility, 
University of Louisville. 
Western blotting: Details have been described previously (102). Briefly, tears and 
protein extracts from human submandibular (HSG) cells (103) and the MCF-7 human 
breast cancer cell line (104) were electrophoresed on a 3-8% NuPAGE Tris-Acetate gel 
(Invitrogen, Carlsbad, CA) and transferred to PVDF membranes (Millipore, 
Marlborough, MA). Western Blot analysis was performed using the DF3 monoclonal 
antibody specific for the tandem repeat region of MUCI (105) followed by horseradish 
peroxidase-coupled sheep anti-mouse Ig. The bands were developed using the 
SuperSignal West Pico detection system (Pierce, Rockford, IL) and visualized using the 
Kodak Image Station 440CF. The chemiluminescent bands and molecular weight bands 
were superimposed electronically in the final Western images. 
Results 
MUCl real-time RT -PCR 
As part of our study of the expression of the polypeptide GalNAc transferase 
glycosyltransferases and their mucin substrates (106), we determined the expression of 
the transmembrane mucin MUCl in human ocular surface tissues. Quantitative real-time 
RT-PCR utilized a Taqman set (referred to here as the MUCl-l set) that spanned the 
boundary between exons land 2 (Fig. 5). Expression in four lacrimal glands was very 
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weak whereas two cornea samples were strong and two were very weak (Fig. 6). Among 
four conjunctivae, three were very strong while the fourth was 200-fold weaker. 
To determine the cause for such large differences of MUCI expression between 
donors, we next tested using a second Taqman set (MUCI-2 set) that targeted the exon 8-
exon 9 boundary (Fig. 5) and found less than a five fold difference between the same 
four conjunctival samples (Fig. 6). This finding indicated that MUC I was actually 
strongly expressed in all four conjunctival samples but that MUCI had not been detected 
by the MUCI-I set in the fourth sample. Electrophoretic analysis of the MUCI-I 
reaction product from the fourth sample revealed that there was in fact a 90 bp product 
instead of the predicted 63 bp product. Repeated analyses, cloning, and DNA 
sequencing revealed that this product contained 27 bp from the 3' end of the first intron; 
this variant sequence has been described previously as the splice variant MUCIIA (see 
Fig. 5) (82;83). This product was not detectable by the Taqman system because although 
the sequences to which the primers annealed remained intact, the sequence to which the 
Taqman probe annealed, namely the exon-exon boundary itself, had been disrupted by 
the addition of the intronic sequence. We had uncovered by chance a conjunctival donor 
who had minimal MUC liB splicing (Fig. 5) at the exon l-exon 2 boundary and instead 
almost exclusively had the MUCIIA splice site variant. 
The MUCIIA splice variant encodes MUCI protein having an additional 9 amino 
acids on the amino terminal side of the tandem repeat region and also is predicted to have 
an altered amino terminus because of a change of signal peptidase cleavage (82;83). 
This additional sequence could alter intracellular trafficking and/or subsequent MUCI 
processing and, therefore, be relevant to MUCI function and ocular surface physiology. 
29 
9 
• MUC1-1 ISJ MUC1-2 
8 :s ~ 
a ~ a 7 a -
a 
...... 
6 x -
......... 
-Q) () 5 r---- -c 
Q) 
~ 
~ 4 r---- - I~-'5 "'0 .E 3 ~ - -
---
--
~ 
...... 
......... 
2 ,---- ~- f--- -
~ 
1 f--- - f------ - ~ ~ ~ 0 '-.,-- ~ 
-
1 2 3 4 5 6 7 8 9 10 11 12 
Sample 
Figure. 6. Expression of MUCI in human ocular surface tissues as determined by 
real-time RT-PCR. Taqman real-time RT-PCR results are expressed as [lI(fold 
difference)] x 10,000; fold difference is the difference between the experimental value 
and 18S rRNA (see Material and Methods). Values are the mean of duplicate Taqman 
data points. Samples: 1-4 conjunctiva; 5-8 cornea; 9-12 lacrimal gland. Lanes (age, 
gender): 1, 74M; 2, 56M; 3, 51M; 4, 72M; 5, 30M; 6, 67M; 7, 47F; 8, 55F; 9, 64F; 10, 
55M; 11, 86F; and 12, 92M. The MUC 1-1 set targets the exon l-exon 2 boundary while 
the MUC 1-2 set targets the exon 8-exon 9 boundary (Fig. 5). 
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MUCI splice variants have been described primarily in tumor tissue, only to a very 
limited extent in normal tissues (95;107), and not at all in ocular surface tissues. For 
these reasons we pursued the expression of MUC 11 A and other MUC 1 splice variants in 
ocular tissues by conventional RT-PCR. 
RT-PCR ofMUCl Splice Variants in Whole Ocular Surface Tissues 
RT-PCR analysis of splice variants MUCIIA and MUCIIB revealed that the first 
two conjunctival samples expressed both variants, the third expressed only MUClIB, and 
the fourth expressed only MUCIIA (Fig. 7, panel I). This latter finding was consistent 
with the real-time RT-PCR results described above. Among the cornea samples, one 
expressed both MUCI/A and MUCIIB, one expressed only MUCIIB and one expressed 
only MUCIIA. A final corneal sample did not express detectable MUCIIA or MUCIIB 
(Fig. 7, panel I, lane 6). However, expression of the ppGaNTases in this sample was 
comparable to that in other corneal samples (data not shown) indicating that the quality 
of the sample mRNA was satisfactory. Therefore, we have no explanation for the very 
low or negative expression of MUCI in this sample. Analysis of a single sample from 
lacrimal gland showed that it expressed only MUCIIA (Fig. 7, panel I, lane 9). 
MUCIISEC, a soluble variant missing the transmembrane domain (83) (Fig. 5), 
was present in all conjunctival and cornea samples but was not detectable in the lacrimal 
gland sample (Fig. 7). These results indicate that if MUCIISEC protein is synthesized 
from these transcripts in conjunctivae and cornea then the protein will be present in tears. 
This report is the first to indicate this possibility. 
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Both MUClIZ(X) and MUClIY are variants lacking the tandem repeat region 
(Fig. 5). MUC lIZ(X) expression was detected in three conjunctival samples and two 
cornea samples while MUClIY was detected in all four conjunctiva and one cornea 
sample. Neither MUCIIY or MUClIZ(X) was detected in the lacrimal gland sample. 
To date we have not detected MUClICT80 or MUClICT58 (95) in any ocular 
surface tissues. However, during the course of sequencing the PCR products of the 
MUClIA and MUClIB amplification, we found a new MUCI splice variant that we have 
termed MUCIIYI (Fig. 5). This variant retains 99 bp from the 5' end of the first intron 
and 27 bp from the 3' end of that intron, and results in a premature stop codon. The 
MUClIYI splice site sequence matches the consensus sequence for alternative splicing 
(Table I) (108). This transcript is predicted to produce a 27 amino acid peptide after 
signal peptidase cleavage (Fig. 8) that has no significant homology to any database 
sequence. We detected the MUCIIYI variant in two of the conjunctival samples, two of 
the cornea samples, and in the lacrimal gland sample (Fig. 7). 
RT-PCR Screening of Conjunctival Swab Samples from Dry Eye Subjects and 
Normal Controls for MUCI Splice Variants 
Because of the possibility that MUC I splice variants could influence ocular 
surface physiology and disease, we screened for MUCI splice variants in brush cytology 
samples of conjunctival epithelium obtained from an initial group of eleven subjects. 
Four out of six samples from dry eye subjects expressed only the MUClIB form while in 
the remaining two dry eye sample one expressed a trace of MUClIA and MUClIB and 
the other expressed both MUClIA and MUClIB (Fig. 9, panel I). In striking contrast 
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Figure 7. RT -PCR of MUCI splice variants in whole ocular surface tissues. Panel I, 
MUCliA and MUClIB splice variants; panel II, MUClfYI; panel III, MUCliSEC; and 
panel IV, MUClIZ(X) and MUClIY. Samples: 1-4 conjunctiva; 5-8 cornea; and 9 
lacrimal gland; lanes 1-9 are in the same order as in Fig. 6. 
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Table I 
Splice sites consensus sequencesa 
Splice 
variant 
Donor Sequence Acceptor Sequence 
MUCIIB ... TGCTTACAG/gtgaggg ... cctaaacccgcaacag/TTGTTA ... . 
MUC 11 A ... TGCTTACAG/ gtgaggg ... c t t ta act t c t t acag/ CTACCA ... . 
MUCIIYI ... GAAGTTAAG/gtaagaa ... ctttaacttcttacag/CTACCA ... . 
a The splice site consensus sequence is (A or C)AG/GT(A or G)AGT at the splice site 
(shown as a back slash); each consensus trinucleotide region is underlined and the bases 
that match the consensus are shown in bold. There is also a polypyrimidine rich area 4 
bases before the 3'end of the intron (splice acceptor) shown in italics. The new splice 
variant (MUCIfYI) matches the consensus sequence. 
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MTPG T Q S P F F L L L L LTV LTG E GIIH E V G S G L peL G G L R G L 
SVGFAPWOMetAPStopSStopATTAPKPATVVTGSGHAS 
Figure 8. Amino acid sequence of the peptide predicted to be encoded by the splice 
variant MUClIYI. The italicized sequence is from exon I, the bold and underlined 
sequence from the first intron, and the remaining sequence from ex on 2. The two 
vertical lines denote the predicted site of signal peptidase cleavage. 
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I 
II 
III 
IV 
Control Dry eye 
1 2 3 4 5 6 7 8 9 10 11 
-- -
--
~ MUC lIA 
MUC lIB 
~ MUC IlYl 
-----~ MUC lISEC 
~ MUC liZ 
MUCIIY 
Figure 9. RT-PCR to detect MUCI splice variants in conjunctival epithelial swab 
samples. Donors: normal controls (lanes 1-5) and dry eye patients (lanes 6-11). Panel: 
I, MUClIA and MUClIB; II, MUC 1 fYI; III, MUClISEC; and IV, MUClIZ(X) and 
MUClIY. Band sizes (in bp): MUCI /A 222; MUClIB 195 ; MUClIYI 145; 
MUClISEC 184; MUCIfY 276; and MUClIZ(X) 329. See Material and Methods for 
primers used. Lanes (age, gender): 1,57 F; 2, 29 F; 3, 61 M; 4, 61 M; 5, 72 F; 6, 63 F; 7, 
85 F; 8, 48 F; 9, 70 F; 10, 74 F; and 11 , 57 F. Electropherogram from the Agilent 
Bioanalyzer DNA 500 chip. 
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samples from two out of five normal control subjects expressed only the MUC 11 A form 
while the other three normal samples expressed both MUCIIA and MUCIIB. None of 
the control samples expressed only the MUClIB variant. The PCR products were 
confirmed by sequencing. A summary of all analyses to date including additional donors 
is shown in Table 2. The results are compared to the distribution of the associated SNP 
rs40n037 (described in section below). The data indicate that the frequency of splice 
variants among the normal donor samples is approaching the frequency expected from 
the population at large based on the SNP data. In contrast the dry eye samples are 
continuing to be enriched in the MUCIIB splice variant while MUCIIA homozygotes 
and heterozygotes are reduced. 
Unlike these differences between the dry eye and normal control samples in 
expression of MUClIA and MUClIB described above, all eleven samples expressed 
MUCI/SEC, MUClIZ(X) and MUCIN (Fig. 9, panels III and IV) while the MUCIIYI 
variant was detectable in four of five normal control samples and three of six samples 
from dry eye subjects (Fig. 9, panel II). In summary, these results indicate a clear 
difference in the expression of the MUClIA and MUCI/B splice variants between dry 
eye patients and normal controls within this initial group of subjects. 
Screening Dry Eye and Normal Control Conjunctival Swab Samples for SNP Status 
as a Measure of Tandem Repeat Size Class 
Hilkens' group previously showed that the SNP at position 8 of ex on 2 in the 
MUC I gene controls alternative splicing at the boundary between exons 1 and 2 (80); 
specifically, the G SNP allele results in the MUClIA splice product while the A SNP 
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Table 2 
Comparison of frequencies of MUC 1 SNP rs4072037 and MUCI splice 
variants a 
Splice site 
Splice variant frequency 
SNP SNP frequency 
Normal donors genotype (%) variant Dry eye (%) donors 
GIG 18 MUClIA only 4/15 (27) 119 (11) 
AlG 49 AB 6/15 (40) 3/9 (33) 
AlA 33 MUCI/B only 5/15 (33) 5/9 (55) 
a SNP frequencies for SNP rs4072037 are from Ensembl website and were determined on 
30 mother-father-child trios from the CEPH collection (Utah residents with ancestry 
from northern and western Europe). Splice variants MUClIA and MUClIB were 
determined by RT-PCR as described in Materials and Methods and shown in Fig. 9, 
panel1. Normal donor group consisted of 6 males, 9 females, average age 55 years; dry 
eye donor group consisted of9 females, average 65.3 years. 
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Splice site status SNP VNTR size class AlwNI Susceptibility 
to dry eye (proposed) 
MUCI/A G Large (60-90) resistant Lower 
MUCI/B A Small (30-45) sensitive Greater 
Figure 10. Relationships among MUClIA and MUClIB splice site status, SNP 
rs40n037 status, MUC1 tandem repeat number, AlwNI sensitivity, and proposed 
susceptibility to dry eye. The relationships between splice site status, SNP rs4072037 
status, and VNTR size class have been established in the literature (80;81). The ranges of 
tandem repeat numbers for the two size classes are shown in parentheses. 
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allele yields the MUC liB variant (Fig. 10). To determine if that relationship holds for 
our population, we determined the status of the SNP in exon 2 using the restriction 
enzyme AlwNI. The G SNP allele is resistant while the A allele is sensitive to AlwNI 
digestion (summary in Fig. 10). We used as starting material for AlwNI digestion the 
products ofPCR used for MUCliA and MUCliB analysis (shown in Fig. 9, panel I). In 
the two samples having only a MUCliA band and not a MUCliB band (Fig. 9, panel I, 
lanes 1 and 5), the MUCliA band was resistant to AlwNI digestion (Fig. 11, lanes 1 and 
5). In the four samples having only a MUCliB band and not a MUCliA band (Fig. 9, 
panel I, lanes 7, 8, 9, and 11), the MUCliB band was sensitive, resulting in two 
fragments of 89 and 110 bp as predicted from the location of the cleavage site (Fig. 11, 
lanes 7, 8, 9, and 11). In the samples with both MUCliA and MUCliB bands, the 
MUCliA band was resistant while the MUCliB band was cleaved (Fig. 11, lanes 2, 3,4, 
6, and 10). 
Overall, we conclude that conjunctival epithelial swab samples containing the G 
allele of the SNP also express the MUC 11 A splice site variant (compare Figs. 9 and 11, 
lanes 1 and 5) while samples containing the A allele of the SNP express the MUC liB 
splice site variant (compare Figs. 9 and 11, lanes 7, 8, 9, and 11). Samples containing 
both splice site choices also contain both SNP alleles (Figs. 9 and 10, lanes 2-4, 6, and 
10). Therefore, we have verified in conjunctival epithelium the relationship between 
SNP status and splice site choice established by Hilkens' group (80). 
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ladder I 
250-
200- --
lSO -
100 -
SO -
2 3 4 5 
- --
6 7 8 9 10 II 
------ - -
.- MUCIIA 
__ Cleaved 
-- MUCI/B 
Figure 11. AlwNI digests of peR products from conjunctival epithelial swab 
samples. PCR products from amplification with primers used for MUCliA and IB (as in 
Fig. 5, panel I) were digested with AlwNI. Samples in same order as Fig. 5: lanes 1-5, 
normal controls; lanes 6-11, dry eye. MUCliA 222 bp. MUClIB products of digestion 
at 89 and 11 0 bp. 
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MUCI Sizes in Tears 
Hilkens' and Swallow's groups have established that there is an association of 
three genetic elements of MUCI; namely, the SNP at position 8 of exon 2, the size class 
of tandem repeats (either large or small), and a CT dinucleotide repeat in intron 6 (80;81) 
(Fig. 10). Based on these relationships, the presence of the MUCIIA splice variant 
should indicate the presence ofMUCI protein with a VNTR region of the long size class 
whereas MUCIIB should predict short VNTR. To provide initial verification of that 
relationship in conjunctival epithelium, we western blotted tears from normal subjects 
with the anti-MUCI MoAb DF3 specific for the tandem repeat (105). Extracts of the 
human submandibular gland (HSG) cell line (103) (Fig. 12, lanes 2 and 8) and the human 
breast cancer cell line MCF-7 (104) (Fig. 12, lane 9) both displayed two reactive species. 
Previously Kufe's group described these two DF3 reactive species in extracts from MCF-
7 cells and concluded that these were the result of two protein cores that differed by 
120,000 daltons and that were encoded by two transcripts of 4.5 and 7.0 kilobases (105). 
Although it was not known at the time, it is now clear that the two DF3 reactive species 
were one large and one small MUCI VNTR size class member. Similarly, the two bands 
from HSG cells represent members of the small and large MUCI tandem repeat size 
classes. Likewise tears from subject 3, whose conjunctival epithelium expressed both 
MUCIIA and MUCIIB splice variants (Fig. 9, panel I, lane 3), produced two major 
bands, one of the long VNTR class and one from the short (Fig. 12, lane 4). The 
differences in migration of the tear bands compared to HSG bands may be due to either 
small differences of tandem repeat number or differences in glycosylation. Tears from 
subject I, whose conjunctival epithelium expressed only MUC 11 A (Fig. 9, panel I, lane 
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1 2 3 4 5 6 7 8 9 10 
210 -- - 210 
Figure 12. Western blot of tears with DF3 anti-MUCl. Electrophoresis was 
performed with a NuPAGE 3-8% Tris acetate gel. After western blotting, bands were 
visualized using the Kodak Image Station 440CF. Lanes: 1 and 10, molecular weight 
markers with the only visible marker being the 210 kD standard; lanes 2 and 8, human 
submandibular gland epithelial cells (HSG) cells extract (103); lane 9, human breast 
cancer cell line MCF -7, used here as a positive control to indicate the locations of large 
and small MUCI VNTR size classes; lanes 3 and 5, tears collected from normal donor 1 
(analyzed also in Figs. 9 and 11 , lane 1); lane 4, tears from normal donor 3 (analyzed 
also in Figs. 9 and 11 , lane 3); and lanes 6 and 7, tears from two other normal MUCIIA 
positive, MUC lIB negative donors. Lanes 1-4 and 5-10 are from two different 
experiments. 
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1), produced a doublet of bands (Fig. 12, lanes 3 and 5) that migrated more slowly than 
either the bands from subject 3, HSG cells, or MCF-7 cells. Similarly, tears from two 
other donors that expressed only MUCliA (data not shown) produced DF3 reactive bands 
that migrated more slowly than the upper band ofHSG and MCF-7 cells (Fig. 12, lanes 6 
and 7). Thus, these results agree with the prediction that a individuals having 
conjunctival epithelium that expresses only the MUCliA splice variant will produce only 
MUCI protein with long VNTR while individuals like subject 3 that express both 
MUCliA and MUCliB splice variants in their conjunctival epithelium will produce 
MUCI protein with both long and short VNTR. 
Discussion 
MUCI Variants in Ocular Tissues 
The mucins are among the many ocular surface components required to maintain 
a healthy ocular surface environment. The major mucins of ocular surface tissues fall 
into two classes: the soluble, gel-forming mucin MUC5AC expressed exclusively by 
conjunctival goblet cells and membrane associated mucins expressed mainly by non-
goblet epithelial cells. In addition MUC2 expression in conjunctiva has been identified at 
the RNA level but as yet not at the protein level. Combining all reported human tissue 
mucins (reviewed in (42;46)), corneas express MUCl, 4,16, and 20; conjunctiva express 
MUC1, 2, 4, 5AC, 7, 13, 15, 16, 17 (109), and 20; and lacrimal glands express MUCl, 4, 
5B, 7, and 20 (110). 
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Previous reports on the presence of mucins in ocular surface tissues did not 
address the question of whether mucin splice variants might be present. In the present 
report we demonstrate the expression at the mRNA level in human ocular surface tissues 
of the MUCI splice variants MUCIIA, MUCIIB, MUCIISEC, MUCIIZ(X), and 
MUC 1 /Y that have all been identified previously in tumor tissue. In addition we describe 
a new variant MUClIYI. 
The presence of these MUCI variants at the ocular surface could have several 
important effects on ocular surface physiology and disease. As mentioned in Results, the 
MUCIIA splice variant has two changes that could effect MUCI processing, namely the 
addition of nine amino acids upstream of the tandem repeat and an altered signal 
peptidase cleavage site (82;83). Whereas transmembrane forms of MUCI mediate cell 
signaling pathways (52), MUCIISEC is missing the transmembrane domain. Therefore, 
MUC IISEC would lack such signaling capability while retaining the extracellular 
functions of the carbohydrate-rich tandem repeat domain. The converse is true of the 
MUCIIZ(X) and MUClIY splice variants which retain signaling possibilities via the 
transmembrane and cytoplasmic domains but lack the tandem repeat region and its 
associated attributes of water retention, lubrication, and barrier function. 
Currently there is considerable interest in the role of complexes between mucins 
and other secreted mucosal proteins in mucosal tissue disease. For example in human 
colon cancer cells, galectin-3 binds to MUC2 (111). A similar complex has been 
described among three MUCI splice variants (112); the transmembrane bound MUCIfY 
variant was shown to bind both MUCIISEC and the soluble, extracellular domain of 
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MUCI/B after its cleavage from the cell surface. Whether such a MUCI self-complex 
exists at the ocular surface awaits future experimentation. 
The MUCIIYI splice variant is predicted to produce a 27 amino acid peptide after 
signal peptidase cleavage (Fig. 8). However, many variant transcripts with premature 
stop codons result in mRNA degradation by the process of nonsense mediated decay 
(113). Therefore, future experiments are required to determine if MUC IIYI peptide is 
actually synthesized in ocular surface epithelial cells. 
MUClIA Splice Variant, Tandem Repeat Number, and Dry Eye Disease 
Our data indicate that among an initial group of nine aqueous deficient dry eye 
subjects only one expressed the MUCIIA variant in the conjunctival epithelium while 
three expressed both MUCIIA and MUCIIB and five expressed only MUCIIB (Table 2). 
In contrast four of fifteen normal control donors expressed only MUCI/A, six expressed 
both MUCIIA and MUCI/B, and five expressed only MUCIIB. Although the difference 
in splice variants between normal and dry eye groups is not statistically significant, the 
normal group percentages are approaching the frequency expected based on the SNP data 
whereas the percentage of MUCIIA positive samples is reduced in the dry eye group. 
Sample collection is continuing to determine the statistical significance of these patterns. 
Based on the above results and the relationship ofMUCI elements established by 
Hilkens' and Swallow's groups (80;81) shown in Fig. 10, we propose the following 
hypothesis: there is a reduced frequency of the MUC 11 A splice variant in ocular surface 
tissues in aqueous deficient dry eye disease and also there is a corresponding drop in the 
number of MUCI alleles with longer numbers of tandem repeats (VNTR) in dry eye. 
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This extension of the hypothesis to tandem repeat length is appealing because it offers an 
explanation for dry eye based on the notion of a reduced number of MUC 1 carbohydrate 
chains being less protective of the ocular surface. The mucin-like domain of MUC1 has 
been predicted to extend 200-500 nm above the cell membrane and far above the 
remainder of the glycocalyx (46;114). Longer VNTR having on average 60-90 tandem 
repeats could clearly provide greater mucin functions of hydration, lubrication, and 
protection than shorter alleles having 30-45 tandem repeats. Also, we should note the 
possibility that apart from its association with VNTR length the MUCIIA variant itself 
could have an impact on ocular physiology because of the differences of amino acid 
sequence from MUCIIB. 
We have provided initial data that supports our hypothesis by showing that donors 
expressing only MUCIIA also had only large MUCI VNTR by western blotting (Fig. 12, 
lanes 3, 5-7). However, formal testing of this hypothesis will require analysis of more 
patient samples to determine: (1) if there is a statistically significant reduction in the 
MUC 11 A splice variant in samples of conjunctival epithelium from dry eye patients as 
compared to age and gender matched controls; and (2) if the MUCI alleles of dry eye 
patients contain shorter VNTR than controls as determined by Southern blotting of 
genomic DNA and western blotting of tears. 
The involvement of MUC 1 in protection of epithelial surfaces has been reviewed 
(47;57;115). For example one strain of MUCI null mice were more susceptible to 
chronic infection and inflammation of the ocular surface and lower female reproductive 
tract than normal controls (66; 116). 
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Several reports have described a relationship between mucin tandem repeat 
number and particular diseases and are listed here as precedents for our hypothesis. Kyo 
et al. reported an association of rare tandem repeat alleles of the intestinal mucin MUC3 
with ulcerative colitis (117). Vinall et al. found an association of gastritis due to H. 
pylori infection with MUCI shorter alleles (118). The salivary mucin MUC7 has two 
common alleles that have either 5 or 6 tandem repeats. Kirkbride et al. have reported 
that MUC7 with 5 tandem repeats is rarer in atopic asthmatics than atopic non-asthmatics 
(119). Swallow's group has found that MUC 1 allele length may effect susceptibility to 
conditions that precede gastric carcinoma (120). They also found longer alleles ofMUC2 
in atopic non-asthmatics compared with normal controls or atopic asthmatics (121). The 
hypothesis of the latter study was essentially the same as that of our current report; 
namely, that a longer mucin VNTR region will decrease access to the cell surface of 
bacteria and other environmental agents as a result of the size, glycosylation, and 
consistency of the mucin. One point to note here is that the differences in tandem repeat 
number in several of those cases is less than what occurs between MUC 1 having high or 
low size groups of tandem repeats; e.g., in the case of MUC3 in ulcerative colitis (117), 
the difference is only between 5 and 6 repeats of MUC3. In contrast in the case of 
MUCI the difference between the large and small size groups is essentially two fold. 
In summary if our hypothesis proves to be correct, it might be possible to predict 
the susceptibility of a person to dry eye disease by testing for the MUCIIA to MUClIB 
ratio by brush cytology. Also, in the future it may be possible to restore MUCIIA levels 
to normal through either gene therapy or selective topical tear supplementation. 
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CHAPTER IV- MUCI AND ESTROGEN RECEPTOR a GENE 
POL YMORPHISMS IN DRY EYE PATIENTS 
The text of this chapter was published in Exp. Eye Research; 88(3):334-8 (2009) 
Introduction 
The mucin MUCl is one of several mucins that function at the ocular surface to 
protect that surface against pathogen invasion, to facilitate lubrication, and to retain water 
(42;46). MUCl is present on corneal and conjunctival epithelial cells (122) and in the 
tears (90). The cytoplasmic domain of MUCl serves as a platform for effectors of 
several cell signaling pathways (123). The large extracellular domain ofMUCl contains 
a variable number of tandem repeat (VNTR) region with each repeat containing five 
potential sites for O-glycosylation. MUCl alleles are divided into size classes that 
contain small (30-45) and large (60-90) numbers of tandem repeats. Among the many 
splice variants of MUC l, two full length variants, MUC liB and MUC 11 A, differ by the 
inclusion of27 bp from intron 1 in MUClIA. 
There are three major types of dry eye syndrome or keratoconjunctivitis sicca 
(KCS) (96). Evaporative dry eye is associated with abnormal tear composition resulting 
in rapid evaporation predominantly due to meibomian gland dysfunction. Aqueous 
deficient dry eye, as the name implies, is associated with inadequate tear production and 
is subdivided into Sjogren's and non-Sjogren's types. Although the epidemiology of dry 
eye has been well studied (67), reports of genetic patterns that might influence 
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susceptibility to dry eye are few. We reported that the frequency of non-Sjogren's 
aqueous deficient dry eye patients expressing only the MUClIA splice variant of the 
mucin MUCI may be lower than in a normal control group (79). Swallow's group had 
previously found an association between MUC 1 splicing and the size class of the MUC 1 
VNTR region (81). Based on those findings, we hypothesized that VNTR length may be 
one factor determining susceptibility to dry eye disease. Another report suggesting a 
genetic factor in dry eye was provided by He et al who found a difference between 
Chinese dry eye and control groups in a polymorphism in estrogen receptor a (ERa) 
(124). In the present study we determined the statistical significance and generality of 
these observations and tested if the MUC I splice variant difference reflected a difference 
in the MUCI VNTR size class. The results indicate a statistically significant difference 
between a normal control group and both non-Sjogren's aqueous deficient and 
evaporative dry eye groups in the MUCI variant genotype frequency. However, the 
association between MUCI variant genotype frequency and VNTR size class was weak 
and did not support the hypothesis that VNTR length was a factor in determining 
susceptibility to dry eye. Finally, in the Caucasian populations tested there was no 
difference between normal control and either of the dry eye groups in ERa variant 
genotype frequency. 
Materials and Methods 
Tissues and DNA: The inclusion of human subjects was in accordance with the 
Declaration of Helsinki and was approved by the local Institutional Review Board and 
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the Human Subjects Protection and Privacy Office of the University of Louisville. 
Informed Consent and Research Authorization were obtained prior to collection of 
samples from enrolled subjects. Non-Sjogren's aqueous deficient dry eye patients were 
identified as having both tear deficiency and ocular surface staining. Evaporative dry eye 
was diagnosed by reduced tear breakup time (TBUT <7 sec) but normal tear production 
(Schirmer test >7 mml5 min) in the presence of meibomian gland obstruction. Ocular 
surface staining was measured by instillation of topical 2% fluorescein solution or 1 % 
lissamine green solution. Fluorescein staining of the cornea and lissamine green staining 
of the conjunctiva was observed at the slitlamp examination in all of the aqueous 
deficient and evaporative dry eye subjects but none of the control group. All subjects 
were female Caucasians. All samples were obtained in Louisville, KY. Subject group 
ages were (mean +/- S.E.): normal controls 59 +/- 2.4 yr., non-Sjogren's aqueous 
deficient dry eye 58.2 +/- 2.4, and evaporative dry eye 66.2 +/- 2.2. 
Buccal swabs were taken with OmniSwabs (Whatman). Genomic DNA was 
extracted from buccal swabs using the QIAamp DNA mini kit and from peripheral blood 
using the Blood & Cell Culture DNA Midi kit (Qiagen). Total RNA was extracted from 
conjunctival brush swabs for splice variant analysis by PCR (79), and tear samples were 
used for western blotting. 
SNP analysis: Single nucleotide polymorphism (SNP) assays (Applied Biosystems) were 
used to determine the frequency of the SNP (rs40n037) that controls the MUCIIA and 
MUClIB splicing event and the SNP (rs2234693) in the ERa gene. 
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Southern and western blotting: Southern blotting analysis of genomic DNA from the 
blood of 29 patients was performed by digesting with Hinfl and probing with a 
digoxigenin labeled MUCI TR DNA probe kindly provided by Dr. M.A. Hollingsworth. 
Western blotting was performed on the tears from 16 patients as previously described 
(79). Briefly, protein samples from tears were electrophoresed on 3-8% NUPAGE Tris-
acetate gels (Invitrogen) followed by incubation with the DF3 antibody specific for the 
MUCI tandem repeat region (l05). The bands were visualized using the Kodak Image 
Station 440CF. 
Results 
Correlation Between MUCI Splice Variant Pattern and SNP Genotype 
Ligtenberg et al. (80) established that the selection of splice variant MUC 11 A or 
MUCIIB was determined by a SNP (rs40n037) in exon 2 of MUCI. We compared the 
presence of the MUCIIA and MUCIIB splice variants and the SNP genotype in our 
subject samples and found a perfect correlation (in 30/30 cases, data not shown). 
Therefore, we analyzed all additional cases by SNP analysis of genomic DNA rather than 
splice variant analysis of cDNA samples. The advantages of SNP analysis were: the 
increased number of volunteers who were willing to donate buccal swab samples as 
compared to conjunctival brush cytology swabs; and the simplicity and speed of sample 
processing and SNP assay of genomic DNA as compared to splice variant analysis of 
cDNA. 
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MUCI SNP Genotype Frequencies Among Normal Controls and Dry Eye Groups 
We conducted a case control study to compare the genotype frequency of the SNP 
(rs40n037) in the MUCI gene between normal control subjects and non-Sj6gren's 
aqueous deficient dry eye subjects as well as evaporative dry eye subjects. All of these 
subjects were female Caucasians from the Louisville, Kentucky area. The SNP genotype 
frequency of the normal control group was statistically different from the non-Sj6gren's 
aqueous deficient dry eye group (P = 0.017) and also from the evaporative dry eye group 
(P = 0.015; Table 3). The non-Sj6gren's aqueous deficient dry eye group was markedly 
low in subjects of the GIG SNP genotype with only one individual being in that category 
(Table 3). This genotype corresponds to the MUCIIA only splice variant (Table 3) that 
we had found to be low in this category of dry eye in our initial report (79). Thus, we 
were able to establish the statistical significance of our observation that we had 
previously reported. 
Given that meibomian gland obstruction is a factor involved in evaporative dry 
eye that is not found in non-Sj6gren's aqueous deficient dry eye, it was surprising to find 
that the evaporative dry eye group was also significantly different than the control group 
in its MUCI SNP genotype frequency (Table 3). However, when the two dry eye groups 
were compared with each other, they were not significantly different (P = 0.09). These 
findings suggest that these two types of dry eye may share a factor or mechanism of 
ocular surface damage related to MUC 1 genotype. 
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Table 3 
MUC 1 SNP genotype frequencies among normal controls and dry eye 
subjects a 
Non-Sj «gren's 
SNP MUC1 splice Normal aqueous Evaporative 
genotypea variant controls deficient dry dryeye b 
eyeb 
GIG A only 7/29 (24%) 1/32 (3%) 3/21 (14%) 
AIG AB 18/29 (62%) 19/32 (59%) 7/21 (33%) 
AlA B only 4/29 (14%) 12/32 (38%) 11/21 (52%) 
a SNP rs40n037 in the MUCI gene. All subjects were female Caucasians from the 
Louisville, Kentucky area. 
b Statistics (Fisher exact probability test 2x3): normal controls versus non-Sj6gren's 
aqueous deficient dry eye P = 0.017 and normal controls versus evaporative dry eye P = 
0.015. 
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Correlation Between MUCI Splice Variant Pattern and VNTR Size Class 
Because of the rough correlation between the MUC1 SNP genotype status and 
VNTR size class established previously (81), we determined if the size class of the 
MUC 1 VNTR contributed to possible protection against damage from dry eye in subjects 
of the MUC1 SNP GG genotype. We analyzed tears by western blotting with the DF3 
antibody specific for the VNTR region of MUC 1. As we previously reported (79), 
extracts from the human submandibular gland (HSG) cell line produce two bands that can 
be used as markers for the large and small VNTR size classes (Fig. 13, lane 7). The GG 
SNP genotype should be associated with the large size class and the AA genotype with 
the small size class. In agreement with this prediction, both GG SNP genotype samples 
shown in Fig. 13 produced bands of the large VNTR size class and both GA genotype 
samples produced one large band and one small band (Fig. 13, lanes 1-4, respectively). 
However, one of the AA SNP genotype samples produced one large VNTR size class 
band and one small band (Fig. 13, lane 5) rather than the two small VNTR bands 
predicted for that genotype and as seen in the other AA sample (Fig. 13, lane 6). Overall, 
the size class of the MUCI protein in tears corresponded to the MUCI SNP genotype in 
only about 80% of the alleles tested (27/32 alleles). 
To evaluate additional dry eye subjects, we conducted Southern blotting of 
genomic DNA from blood because of the limited tear volume in many aqueous deficient 
dry eye subjects. For each MUC1 SNP genotype, there were samples in which the 
VNTR size class agreed with the SNP genotype (GG genotype corresponding with only 
the large size class of VNTR, AA genotype having only the small size class, and GA 
genotype having both size classes as in Fig. 14, lanes 3, 5, 7, and 9) and samples in which 
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SNP GG SNP GA SNP AA 
1 2 3 4 5 6 7 
Figure 13. Western blot analysis of tears with DF3 anti-MUCI. Tears (5 JlI) from 
normal control donors were western blotted with anti-MUCI antibody DF3. Lanes 1 and 
2, SNP GG genotype; lanes 3 and 4, SNP GA genotype; lanes 5 and 6, SNP AA 
genotype; and lane 9, extract from the human submandibular gland (HSG) cell line cells 
(positive control for SNP GA heterozygote to show migration of large and small VNTR). 
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Figure 14. Comparison of MUC1 SNP genotype and VNTR allele size as 
determined by Southern blotting. Genomic DNA was isolated from nine subjects of 
the MUCI SNP genotypes indicated at the top. Southern blotting distinguished VNTR 
allele lengths in the large size class (region of 80 repeats) and small size class (region of 
40 repeats). MUCI allele lengths agreed with the SNP genotypes in 46 of the total of 58 
alleles analyzed (79% agreement). M, markers with lengths given in kb. 
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the VNTR size class disagreed with the SNP genotype (lanes I, 2, 4, 6, and 8). Similar to 
the western results, the SNP genotype correlated with the VNTR in only 46 of 58 (79%) 
of the alleles analyzed. Therefore, these results suggested that VNTR size class was 
probably not associated with susceptibility to dry eye. 
ERa SNP Genotype Frequencies Among Normal Controls and Dry Eye Groups 
He et al. (124) used the Pvull restriction enzyme to analyze a polymorphism in 
intron 1 of the ERa gene and found a significant difference in the genotype frequency 
between normal controls and patients with dry eye among Chinese subjects (Table 4). 
We determined if this polymorphism frequency difference between dry eye subjects and 
normal controls occurred in Caucasians. We utilized a simpler and more rapid SNP assay 
to determine the genotype frequency of that polymorphism (Table 4). Neither the non-
Sjogren's aqueous deficient dry eye group nor the evaporative dry eye group was 
different from the normal control group. Therefore, these results did not support the 
possibility that this ERa polymorphism could be used in Caucasians to distinguish 
normal controls from dry eye subjects. 
Discussion 
ERa SNP Genotype Frequencies Among Caucasians 
He et al. reported a significant difference between Chinese normal control and dry 
eye groups in genotype frequency of a polymorphism in the ERa gene (124). Based on 
reported reduced values for tear break up time and Schirmer strip migration, these 
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Table 4 
ERa SNP genotype frequencies among normal controls and dry 
eye subjectsa 
Pvull Pvull Pvull SNP Normal Non-Sjogren's 
pheno- freq. freq. geno- controlsb,c aqueous 
types· normal dry eye typeb deficient dry 
controls 0/0· eyeb,C 
0/0· 
PP 11 20 CIC 5/21 (24%) 7/24 (29%)C 
Pp 64 43 CIT 9/21 (43%) 9/24 (38%) 
pp 25 37 TIT 7/21 (33%) 8/24 (33%) 
Evap-
orative 
dryeyeb,C 
5/22 (23%)C 
13/22 (59%) 
4122 (18%) 
a Pvull restriction enzyme phenotypes and frequencies for Chinese subjects from He et 
al. (124) 
b SNP rs2234693 in the ERa gene. Caucasian subjects from the same groups in Table 1. 
e Statistics (Fisher exact probability test 2x3): normal controls versus non-Sjogren's 
aqueous deficient dry eye P = 0.93 and normal controls versus evaporative dry eye P = 
0.48. 
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patients may have been of the non-Sj6gren's aqueous deficient dry eye type. However, 
because there was no indication whether meibomian gland disease was specifically 
excluded, we cannot rule out the possibility that these patients might have been of the 
evaporative dry eye type or a combination of both types. In contrast to the genotype 
frequency differences in the Chinese population, we could not detect any difference in 
genotype frequency between normal controls and either the non-Sj6gren's aqueous 
deficient dry eye group or the evaporative dry eye group when we analyzed this 
polymorphism in Caucasian subjects (Table 4). Thus, we have no evidence that this ERa 
polymorphism plays a role in susceptibility to dry eye in Caucasians. However, this ERa 
SNP analysis does provide a control for our MUCI SNP results in that the ERa SNP data 
indicate that we did not inadvertently sample from different populations when we 
collected our normal controls and dry eye subjects from Kentucky. 
MUCI SNP Genotype Frequencies Among Caucasians 
Our results indicate that the GIG genotype of the MUCI SNP rs40n037 has a 
much lower frequency in non-Sj6gren's aqueous deficient dry eye subjects with ocular 
surface staining as compared to normal controls (Table 3). This result confirms our 
initial observation (79) and suggests that this genotype may offer protection against the 
development of this type of dry eye disease. It is important to point out here that we 
classified these patients not only as having non-Sj6gren's aqueous deficient dry eye but 
also as having ocular surface staining. Therefore, the MUC 1 genotype may be related to 
protection of the ocular surface from damage rather than being related to the etiology of 
this type of aqueous-deficient dry eye disease (see Section below). The same rationale 
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may apply to evaporative dry eye. Meibomian gland disease is known to be a component 
in the etiology of evaporative dry eye. It was surprising to find that two different types 
of dry eye disease both have MUCI SNP genotype frequencies that differed significantly 
from the normal control group (Table 3). A possible explanation could be that both 
disease subtypes share mechanisms leading to damage to the ocular surface rather than 
sharing mechanisms responsible for the primary etiology of each disease subtype. 
Dry eye disease is now considered to be an inflammatory disorder that affects the 
ocular surface (125). Inflammation of the lacrimal gland, the meibomian gland, and the 
ocular surface has been shown to play a critical role in the pathogenesis of dry eye 
(27;34). Increased levels of inflammatory mediators including pro-inflammatory 
cytokines, human leukocyte antigen (HLA-DR) and intercellular adhesion molecule 
(ICAM)-I, have been demonstrated in the tears and in the conjunctival epithelium of dry 
eye patients (19; 126). The drop in estrogen and androgen levels during menopause is 
associated with increased cytokine production and inflammatory disease (127; 128). 
MUCI has been shown to modulate inflammation although the details of the role of 
MUCI are presently unclear. MUCI ablation experiments in mice showed an increase in 
inflammatory response indicating an anti-inflammatory role of MUCI (65). Moreover, 
MUCI expressed on resting T lymphocytes can inhibit the activation of T cells (68). In 
addition, it was recently reported that MUCI can inhibit the activation of Toll-like 
receptors (129). In contrast to those three reports ofMUCI as an inflammatory inhibitor, 
MUCI was recently shown to activate the NF-KB pathway in both normal epithelial cells 
and cancer cell lines (69), thus suggesting a possible pro-inflammatory role of MUCl. 
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Future studies will be required to clarify the precise role ofMUCl in the development of 
damage to the ocular surface in dry eye syndrome. 
Possible Relationships of MUCl Variants in Dry Eye Disease 
Ocular surface damage as evidenced by staining of the cornea and conjunctiva by 
fluorescein and lissamine green stains is a frequent consequence of dry eye disease (96). 
Staining of the surface epithelial cell by lissamine green and rose bengal dyes has been 
explained by loss of the protection of those cells by alteration of the glycocalyx that 
covers those cells (36). Fluorescein staining of the corneal epithelium is attributed to 
damage to the epithelial cell membranes (44). It is possible that variations in the MUCI 
glycoprotein determine susceptibility to ocular surface damage through either diminished 
protection of the surface or inflammation modulated damage to the surface cells. 
The most likely explanation for the observed differences of rs40n037 allele 
frequencies between dry eye patients and controls is the unique splice acceptor site for 
ex on 2 for MUClIB (A allele) located 27 bp upstream of the one used by MUCIIA (0 
allele). As a result, MUClIA protein as compared to MUClIB contains nine additional 
amino acids on the amino terminal side of the tandem repeat region. This additional 
sequence is predicted to change the signal peptidase cleavage site thereby altering the 
amino terminus of the mature protein (82;83). These two sequence changes could alter 
intracellular trafficking and/or subsequent MUCI processing and, therefore, be relevant 
to MUCI function and ocular physiology. The general structure of MUCl as a large 
transmembrane protein allows it to sense the external environment and to communicate 
that signal inside the cell via signal transduction mediated by the cytoplasmic domain. 
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Consequently, the change in the N-terminus of the extracellular domain corresponding to 
MUCIB could potentially alter the interaction of MUCI with extracellular components 
thereby increasing the ability of the cell to respond to stimuli. 
In addition to the possible involvement of MUC 1 in modulating inflammation 
described above, there are at least three other ways that MUCI variants could be related 
to susceptibility to dry eye ocular surface damage. First, the SNP could be associated 
with a previously undescribed sequence difference in the exons encoding the cytoplasmic 
domain. However, using PCR we amplified and sequenced the cytoplasmic domains of 
MUCI from two MUCIIA only and two MUClIB only cases and found that the 
sequences were identical (data not shown). Therefore, this possibility was ruled out. 
Second, Swallow's group established that the MUCI polymorphism studied in this 
report correlates with the size class of the VNTR tandem repeat region (either large or 
small), and a CT dinucleotide repeat in intron 6 (81); i.e., the SNP genotype G produces 
MUCI/A and is associated with large tandem repeat alleles while the SNP genotype A 
that produces MUC liB is associated with small alleles. Based on this relationship, we 
initially hypothesized that the different MUCI splice variant pattern in non-Sjogren's 
aqueous deficient dry eye patients could reflect a difference in the tandem repeat size 
(79); i.e., dry eye patients deficient in expression of the MUCIIA variant would have a 
lower number of tandem repeats, and therefore, reduced O-glycosylation of MUCI and 
less protection of the ocular surface. However, western and Southern blotting (Figs. 13 
and 14) revealed that the correlation between the MUCI SNP genotype and tandem 
repeat size class held in only about 80% of the cases. This less than perfect correlation 
agreed with the results of Swallow's group (81). Based on these results, it appears 
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unlikely that MUCI tandem repeat size IS responsible for susceptibility to dry eye 
disease. 
Third, if the MUC 1 SNP was inherited as part of a haplotype, then another genetic 
element within that haplotype could be the functional entity involved in susceptibility to 
dry eye rather than MUC 1 itself. In fact there are three other SNPs with significant (r2 > 
0.8) inheritance with the MUCI SNP (see Haploview in the HapMap project). Two of 
these SNPs (rs2049805 and rs2990245) are in the intergenic region between the metaxin 
1 and the glucerebrosidase (GBA) genes; one SNP (rs2066981) is intronic in the 
thromospondin 3 precursor (THBS3) gene; and one SNP rs364897 is in the ~­
glucocerebrosidase (GBA) gene. The latter SNP appeared to be the most promising 
candidate because it was the only non-synonymous SNP, coding for a Ser/Asn change, 
and also because GBA has been associated with epithelial hydration and maintenance of 
the epithelial permeability barrier (130). The minor allele frequency of this SNP in the 
Caucasian population reported by the HapMap was 0.42. However, we could not detect 
any samples positive for the minor allele using a Taqman SNP assay (data not shown) on 
the same samples from our patient populations used for the other SNP assays described 
here. We concluded that this SNP does not exist in the Caucasian population at least at 
the frequency stated by Hap Map. Therefore, if another element in the haplotype with 
MUCI is the functional entity in dry eye, it remains to be identified. 
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CHAPTER V- MUClIA AND MUClIB SPLICE VARIANTS DIFFERENTIALLY 
REGULATE INFLAMMATORY CYTOKINE EXPRESSION 
Introduction 
As discussed in Chapters I-IV, MUCI variants are hypothesized to playa key role 
in the development and progression of dry eye disease. The MUCIIA splice variant 
differs from the MUClIB form by having an additional 9 aa within the MUC1-N domain 
(Figure 3). As stated in Chapter II, this additional sequence is predicted to change the 
signal peptidase cleavage site, thereby altering the localization signal within the amino 
terminus (82;83), and potentially changing its intracellular trafficking and/or subsequent 
processing. Although much is known about how the MUCI CT regulates signal 
transduction (131), the contribution ofMUC1-N in the cell signaling properties ofMUCl 
is poorly understood. A change in the MUC1-N domain may alter the interaction of 
MUC 1 with extracellular components, thereby changing cellular to responses to external 
stimuli. Alternatively, the change in signal peptide sequence may alter intracellular 
location and thus intracellular signaling events. The impact of the 9 additional aa in the 
MUC1-N in MUCIIA versus MUClIB on the intracellular localization and signaling 
functions ofMUCl has not been examined. 
The goal of the studies described in this chapter was to elucidate the roles of the 
MUCIIA and MUClIB splice variants in regulating cellular inflammatory responses to 
tumor necrosis factor alpha (TNFu). The importance of examining MUCI splice variants 
from the standpoint of inflammatory responses is two fold: first, MUCI has been 
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demonstrated to play an important role in regulating inflammatory responses VIa 
modulation of the NF-KB pathway both in vitro and in vivo (65;67;69). Second, dry eye 
disease is considered to be a chronic inflammatory disorder that affects the ocular surface 
(125). Thus, determining the roles of MUCIIA and MUClIB splice variants in the 
regulation of inflammation will provide insight into the pathogenesis of dry eye disease. 
In this report, we demonstrate that MUClIB and MUCIIA splice variants differ in their 
ability to modulate certain TNFa-induced inflammatory responses. 
Materials and Methods 
Cell Culture: COS-7 cells were purchased from American Type Culture Collection. 
COS-7 cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM, 
Invitrogen) supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals). 
Plasmids and MUCIIA cloning: The MUClIB and MUClilEX in pCMV-DNA3 
(pCDNA3) constructs were a kind gift from Dr. lA. Schroeder at the Arizona Cancer 
Center, University of Arizona. The MUClIB cDNA was originally cloned by M.A. 
Hollingsworth at the University of Nebraska Medical Center as described in (132). The 
MUClIB cDNA was subcloned into HindIIIIEcoRI sites of Litmus38i vector (NEB) 
using standard techniques. MUClIB in Litmus38i was digested using XmnI and BsmI 
restriction enzymes (NEB). The additional 27 bp present in the MUCIIA variant was 
cloned into XmnI and BsmI sites of MUClIB using In-Fusion cloning (Clontech). 
Briefly, a 262 bp fragment containing the 27 bp corresponding to the MUCIIA splice 
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variant (44;79) was generated by PCR using cDNA from a MUCIIA homozygous donor 
and the following primers: 5'-CCT GCC TGA ATC TGT TCT GC-3' (forward) and 5'-
CTG GAG AGT ACG CTG CTG GT-3' (reverse). These primers are flanking the XmnI 
and BsmI sites in exons land 2 of the MUCl gene, respectively. The amplification 
protocol consisted of an initial denaturation of 94°C for 1 min, 35 cycles of denaturation 
at 94°C for 30 s, annealing at 60°C for 30 s, and extension at 72 °C for 30 s. The PCR 
product was ligated into pCR®-Blunt II-TOPO® vector (Invitrogen). In-Fusion PCR was 
performed to generate a 252 bp product using pCR®-Blunt II-TOPO® vector as a template 
and the following primers: 5'- CAG CGC CTG CCT GAA TCT GTT CTG CCC CCT 
CCC CA-3' (forward) and 5'-TCA TCC TTG TAA TCA GCA TTC TTC TCA GTA 
GAG CT-3' (reverse). In-Fusion Dry down reaction (Clontech) was used to ligate 
MUClIA into the MUCIIB Litmus vector. The reaction mixture was transformed into 
One Shot Machl-Tl competent E.coli (Invitrogen). Plasmid DNA from clones was 
sequenced to confirm correct ligation and the integrity of the full length MUCIIA 
sequence in pCDNA3. 
Transfection of COS-7 cells: Cells were seeded in six-well plates at a density of 1 x 105 
cells/well. Cells were transfected with 1 Ilg of MUClIA, MUCIIB, MUCl~EX or 
pCDNA3 (empty vector, EV) using FuGENE 6 reagent (Roche). 
F ACS: Transfected COS-7 cells were harvested at 24, 48 and 72 h and stained using M2 
anti-FLAG antibody (M2, Sigma) diluted in PBS containing 5 % FBS and sodium azide. 
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Stained cells were analyzed usmg a F ACS calibur (Becton Dickinson). Cell Quest 
Software 1.2.2 was used for acquisition and analysis of each cell sample (n = 10,000). 
WCE and western blotting: WCE were prepared by incubating the cells for 30 min in 
lysis buffer (20 mM Tris pH 7.5, 150 mM NaCI, 1 % NP40 and 5mM EDTA pH 8.0) 
containing protease inhibitors (Roche). Protein concentrations were determined by a 
Bradford assay (BioRad). Proteins were separated on 14 % Tris-Glycine gels (Invitrogen) 
and transferred to PVDF membranes (Millipore). The membranes were blocked 5 % 
nonfat milk in PBS-T (0.1 % Tween20) and immunoblotted with the indicated antibodies. 
Armenian hamster against MUCI-CD (CT2, Thermo Scientific), ~-actin (Sigma), TGF~ 
(Cell Signaling), DF3 against MUC I-N (Signet). HyGlo chemiluminescent HRP 
antibody detection reagent (Denville Scientific) was used to detect protein bands. The 
membranes were visualized on Kodak Biomax ML film (VWR). Resulting immunoblots 
were scanned using a Microtek ScanMaker i800 scanner (Carson). Un-Scan-It 6.1 for 
Windows (Silk Scientific) was used to quantitate the integrated optical densities (IOD) 
for each band and analyze the relative amounts of immunoreactive protein, based on pixel 
density as previously described (133). 
Immunofluorescence: Cells were seeded onto glass coverslips and allowed to grow 
overnight to approximately 50% confluency. Cells were transfected with MUClIA, 
MUClIB, MUCl~EX or pCDNA3 (empty vector) as above. Cells were washed once 
with PBS and chilled on ice for 10 min. The cells were then incubated in cold 5 % MEM 
with M2 anti-FLAG antibody (Sigma) at a dilution of 1: 1000 for I h at 4°C. After 
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incubation with the primary antibody the cells were washed three times with ice-cold 5 % 
MEM followed by incubation with goat anti-mouse DyLight 488 conjugated (Invitrogen) 
and wheat germ agglutinin (WGA) Alexa Fluor 633 conjugated (Invitrogen), both diluted 
I :200 in cold 5 % MEM. After incubation in secondary antibody, the cells were washed 
three times with cold PBS and fixed on ice for 15 min in 4% para-folmaldehyde. The 
cells were then washed once in PBS and mounted with ProLong Anti-fade (Invitrogen). 
Images were captured using an Olympus FVIOOO confocal microscope. Imaging was 
performed with appropriate single-color controls with individual channels recorded 
sequentially. 
RNA isolation, RT-PCR, and quantitative real-time RT-PCR CQRT-PCR): Total RNA 
was extracted using RNeasy microcolumns (QIAGEN) according to the manufacturer's 
protocols. Reverse transcription was performed by using random hexamers and the High-
Capacity cDNA Archive Kit (Applied Biosystems). QRT-PCR was performed with the 
ABI PRISM 7900 SDS 2.1 (Applied Biosystems) by relative quantification with standard 
thermal cycler conditions. TaqMan primers and probes for IL-l~, IL-8, TGF~, PDCD4 
and control gene 18S rRNA were purchased as Assays-on-Demand Gene Expression 
Products (Applied Biosystems). Expression of each target gene was determined in 
triplicate and normalized to I8S rRNA. Analysis and fold differences were determined 
using the comparative CT method. Unless otherwise indicated fold change was calculated 
from the MeT values with the formula T ilACT . Experiments were repeated 3-4 times 
and values averaged. 
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MTT Assays: COS-7 cells seeded onto 96-well plates at a density of 2000 cells/well and 
allowed to grow overnight. Cells were transfected in quadruplicate with 0.05/-lg plasmid 
DNA: EV, MUClIA, or MUClIB using FuGENE HD (Roche). Cell proliferation was 
determined using the CellTiter 96® AQueous One solution Cell proliferation Assay 
(Promega) following the manufacturer's protocol. The absorbance was recorded at 
490 nm using a SpectraMax M2 microplate reader (Molecular Devices). 
ELISA: COS-7 cells were transfected with EV, MUClIA, MUClIB or MUCl~EX 
expression vectors in six-well plates. After 48 h incubation, cells were treated with 10 
ng/ml TNFu (Prepotech) for 24 h and media was collected. The media was concentrated 
using Amicon ultra 10K centrifugation columns (Millipore). IL-8 quantification was 
performed using a kit from BD Biosciences and following manufacturer's protocol. 
NF -KB Luciferase reporter assay: COS-7 cells were seeded in 24-well plates at a density 
of 2.5 x 104 cells/well and transfected as described above. Each well received 250 ng of 
a NF-KB luciferase reporter (Promega), 5 ng of a Renilla luciferase reporter (pRL-tk) 
from Promega and 500 ng plasmid DNA for EV, MUClIA, MUClIB or MUCl~EX. 
Forty-eight h after transfection, triplicate wells were left untreated or treated with 1 or 10 
ng/ml TNFu. The cells were harvested 4 and 24 h after treatment using Promega's 
Passive Lysis buffer. Luciferase and Renilla luciferase activities were determined using 
Promega's Dual Luciferase assay in a Plate Chameleon luminometer (BioScan, 
Washington, DC). Firefly luciferase was normalized by Renilla luciferase to correct for 
transfection efficiency. Fold induction was determined by dividing the averaged 
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normalized values from each treatment by the untreated value for each transfection 
condition. 
miRNA isolation and QRT -PCR: COS-7 cells were seeded in six-well plates at a density 
of 1 x 105 cells/well and transfected as described above. After 48 h incubation, cells were 
treated with 10 ng/ml TNFa (Prepotech) for 24 h. miRNA-emiched total RNA was 
extracted from cells using the miRCURYmiRNA isolation kit (Exiqon). The quality and 
quantity of the isolated RNA was analyzed using a NanoDrop spectrophotometer and 
Agilent Bioanalyzer. cDNA was synthesized using the miRCURY LNATM first strand 
cDNA synthesis kit (Exiqon) and QPCR performed using the miRCURY LNA ™ SYBR 
Green master mix (Exiqon) using the miRNA primer set for miR-21 (Exiqon). 5S RNA 
was used for normalization of miRNA expression. Analysis and fold change was 
determined using the comparative threshold cycle (Ct) method. The change in miRNA 
expression was calculated as fold-change, i.e., relative to untreated (control). 
MUC 1 ectodomain release: Conditioned media was collected from transfected COS-7 
grown in six-well plates and treated with various concentrations ofTNFa for 24 h. 500 III 
of media was concentrated to 15 III using Amicon ultra 10K columns (Millipore). 13 III 
of conditioned media was separated on 3-8% Tris-acetate gels (Invitrogen) and 
immunoblotted with DF3 Mab (Signet) to MUCI-N. 
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Statistical analyses: Results are expressed as mean ± S.E.M of 3-5 independent 
experiments in which each treatment was done in triplicate. Student's t test was 
performed when indicated. p < 0.05 was considered significant. 
Results 
Expression of MUClIA and MUClIB Splice Variants in COS-7 cells 
To determine the functional consequence of the extra 9 aa present at the MUCI-N 
domain of MUC 11 A, the additional 27 bp from the exon 1-2 junction and SNP in exon 2 
was successfully inserted into the MUClIB vector (134) (Fig. 15A). The FLAG tag was 
preserved in the MUCI/A construct for ease of screening. The MUCIL\EX expression 
vector was used to determine the contribution of the MUCI-N domain in the regulation 
of inflammatory cytokine production. As shown in Fig. 15A MUCIL\EX lacks most of 
the MUCI-N. 
Although previous investigators showed that MUC liB was correctly localized to 
the plasma membrane (PM) (134), this is the first evaluation of the cellular localization 
and function of the MUCI/A splice variant. To compare the cellular distribution of 
MUClIA and MUClIB, COS-7 cells (MUC1-null) were transiently transfected with each 
construct. The transfection efficiency and MUClIA and MUClIB protein expression 
levels were determined by flow cytometry using the FLAG antibody (Fig. 15B) and 
western blot using an antibody specific for the MUCI-CD (Fig. 15C). Cell surface 
MUClIA and MUClIB expression was detected in ~ 20-35 % of the cells 24-72 h after 
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Figure 15. Expression of MUClIA and MUClIB in COS-7 cells. (A) Schematic 
diagram ofMUClIA, MUClIB and MUCILlliX constructs used for transfection of COS-
7 cells. The insertion of the FLAG tag within the N-terminal domain (NTD) is indicated. 
There are 42 tandem repeats (TR) in both MUClIA and MUClIB whereas MUCIL1EX 
lacks the tandem repeat. The transmembrane (TM) and C-terminal domains (CD) are 
indicated. * indicates the SNP and nucleotide change between MUClIB and MUCI /A. 
The black box indicates the additional 27 bp in MUClIA. (B) Flow cytometry analysis of 
FLAG expression in COS-7 cells 24, 48 and 72 h post-transfection using M2 anti-FLAG 
antibody and PE-conjugated secondary antibody. Values are from one representative 
FACS analysis. (C) Western analysis of MUCI protein expression in WCE from COS-7 
cells either untransfected (UTx), transfected with the empty vector (EV), a mock control 
(no DNA), or expression vectors for MUCI /A or MUCI /B for 24,48 and 72 h. 6 Ilg of 
WCE from MCF -7 cells was loaded into the far right lane as a positive control for 
MUCI. The blot was probed with CT2 anti-MUCI antibody (Labvision) and ~-actin 
(Sigma) which was used as a loading control. The bar graph shows the quantitation of 
MUClIA and MUClIB relative to ~-actin expression relative to MCF-7 that was set to 
one for comparison. 
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transfection (Fig. 15B). These results indicate that MUClIA and MUClIB localized to 
the PM, as seen for native MUClIB in epithelial cells (135). Western blots of whole cell 
extracts showed that the levels of MUC II A and MUC liB protein expression in COS-7 
cells 24, 48 and 72 h post-transfection were similar (Fig. 15C), confirming the FACS 
data. The expression of endogenous MUCI in MCF-7 human breast cells, which have 
high MUCI expression (136), is shown for comparison. The highest expression of 
MUClIA and MUClIB was achieved 48 h after transfection. Thus, this time of 
transfection was used for further experiments to characterize MUClIA and MUClIB 
function. Overexpression of MUClIA and MUC-IB had no effect on COS-7 viability 
(Fig. 16). 
To further evaluate PM localization of MUClIA and MUClIB, 
immunohistochemistry was performed on nonpermeabilized COS-7 cells using an anti-
FLAG antibody and Alexa-Flour-conjugated wheat germ agglutinin (WGA) as a PM 
marker. The PM localization of the MUCI~EX protein was evaluated in parallel. The 
MUCI~EX expression vector contains the transmembrane domain (Fig. 15A) and is 
therefore expected to localize to the PM; however no one has evaluated the cellular 
localization of MUC1~EX. As shown in Figure 17, MUClIA, MUClIB and 
MUC1~EX, all localize to the PM of COS-7 cells as indicated by the overlap in signal 
(yellow) with WGA. No difference was observed between MUClIA, MUClIB and 
MUCI~EX protein localization. The empty vector (EV, negative control) control panel 
demonstrates the specificity of the FLAG antibody. 
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Figure 16. Expression of MUClIA and MUClIB in COS-7 cells does not affect cell 
viability. COS-7 cells were transfected with the empty vector (EV), MUClIA, or 
MUC lIB. After 1, 2, 3, 5, and 7 days, cell viability was measured by MIT assay. 
Values are the average of quadruplicate determinations within one experiment ± SEM. 
This experiment is representative of two experiments that showed similar results. 
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Figure 17. Surface expression of MUClIA and MUClIB in COS-7 cells. COS-7 cells 
were transfected with the empty vector (EV, negative control), MUClIA, MUClIB, or 
MUClllEX as described in Materials and methods. Forty-eight hours after transfection, 
the cells were stained with the M2 anti-FLAG antibody (green) and Wheat Germ 
Agglutinin (WGA, red) as a plasma membrane marker. Images were captured using an 
Olympus FVIOOO confocal microscope. The colocalization of FLAG and WGA is 
indicated in yellow in the merged image. 
76 
Regulation of the Inflammatory Response by MUClIA and MUClIB 
Previous research indicates that MUClIB has both anti-inflammatory and pro-
inflammatory properties (67;69;137). To determine if MUClIA and MUClIB 
differentially modulate inflammatory responses, COS-7 cells were transfected with EV, 
as a negative control, MUClIA, MUClIB or MUC1~EX for 48 h. Cells were treated 
with 10 ng/ml TNFa for 4 and 24 h to initiate the inflammatory response (138;139). 
QRT-PCR was used to determine the mRNA levels of pro-inflammatory cytokines 
known to be induced by TNFa: IL-1~ (140) and IL-8 (141). Because IL-8 and TNFa are 
increased in the tears of patients with dry eye disease (142; 143), IL-8 regulation by 
MUC1 splice variants is relevant to this study. COS-7 cells transfected with EV and then 
treated with TNFa exhibited a 12- and 40-fold increase in IL-1~ and IL-8 mRNA at 4 h, 
respectively (Fig. 18A). There was a statistically significant decrease in 4 h TNFa-
induced IL-1 ~ and IL-8 expression in COS-7 cells expressing either MUC liB or 
MUC1~EX compared to the EV control. In contrast, MUClIA-expressing cells did not 
attenuate the induced expression ofIL-1~ after 4 hrs ofTNFa. At the 4 h time point, the 
TNFa-induced expression of IL-8 was also inhibited in MUClIA expressing cells 
compared to EV. After 24 h of TNFa, COS-7 cells expressing MUClIA exhibited an 
increase in IL-1~ and IL-8 compared to EV-transfected cells. Interestingly, MUClIB or 
MUC1~EX no longer inhibited the induction ofIL-1~ and IL-8 mRNA after 24 h TNFa 
treatment. 
To confirm the differential regulation of IL-8 expreSSIOn by MUClIA and 
MUC liB, the amount ofIL-8 protein released into the media of transfected COS-7 cells 
was examined 24 h after TNFa treatment (Fig. 18B). Cells transfected with MUClIA 
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Figure 18. MUClIA and MUClIB differentially regulate IL-1~ and IL-8 expression. 
COS-7 cells were transfected with empty vector (EV), MUClIA, MUClIB, or 
MUCI~EX for 48 h. Cells were left untreated (UT) or treated with 10 ng/ml TNFa for 4 
and 24 h. (A) QRT-PCR analysis of IL-I~ or IL-8 mRNA was performed. TNFa-
induced expression in EV -transfected cells at 4 h was set to one for comparison. There 
was ~ 12-fold induction of IL-I~ and 40-fold induction of IL-8 with TNFa treatment 
relative to basal. (B) COS-7 cells were treated for 24 h with 10 ng/ml TNFa. IL-8 
protein levels were measured in the cultured media by ELISA. Values in panels A and B 
are the mean ± SEM of 3-5 experiments. *, p<O.05 compared to EV. **, p<O.OOI 
compared to EV. #, p<O.05 compared to MUClIA. ##, p<O.OOI compared to MUClIA. 
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released 5-fold more IL-8 protein compared to cells transfected with the EV control. No 
change in IL-8 protein secretion was observed in cells expressing MUCliB or 
MUC1.-1EX compared to EV. These data agree with the 24 h mRNA data for IL-8 shown 
in Fig. 18A. 
MUClIA Increases Basal TGFfl mRNA and Protein Expression 
MUC 1 exerts anti-inflammatory activity in response to Pseudomonas aeruginosa 
in vivo and in vitro (65;137;144). Because TGFfl is a potent anti-inflammatory cytokine 
(145), we examined whether MUCliA and MUCliB regulate TGFfl expression. 
Interestingly, MUC 11 A overexpression in COS-7 cells significantly increased basal 
TGFp mRNA levels (Fig. 19A). In contrast, no change in basal TGFp mRNA was 
detected in MUCliB or MUC1.-1EX overexpressing cells. TNFa increased TGFp mRNA 
by at least 1.5-fold compared to untreated in EV, MUCliB or MUC1.-1EX-transfected 
cells, but not in MUCliA-transfected cells. TNFa-induced levels of TGFp mRNA were 
comparable in EV, MUCliB or MUC1.-1EX transfected cells. Western blot analysis of the 
TGFp precursor protein revealed an increase in basal TGFp protein in the MUClIA-
tranfected COS-7 cells compared to EV-, MUClIB- and MUC1.-1EX- transfected cells 
(Fig. 19B). These data demonstrate that changes in the structure of the MUCl 
extracellular domain (MUC1-N) alter downstream signaling resulting in differential 
regulation of basal and TNF-a induced TGFp expression. 
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Figure 19. MUClIA stimulates TGF~ expression. COS-7 cells were transfected with 
EV control, MUClIA, MUC lIB, or MUClLillX for 48 h prior to treatment with 10 ng/ml 
TNFa for 6 h, UT= untreated. (A) QRT-PCR analysis ofTGF~ mRNA was performed. 
TGF~ expression in EV-transfectedlUT cells was set to one for comparison. Values are 
the mean ± SEM of 3 experiments. *, p<O.05 compared to EV -UT. #, p<O.05 compared 
to MUClIB or MUCli1EX UT. (B) Western blot analysis ofTGF~ precursor expression 
in WCE (6 jlg). The blot was probed with TGF~ antibody (Cell Signaling) and then 
stripped and reprobed for ~-actin as a loading control. This blot is representative of two 
blots that showed the same results. 
80 
Regulation ofNF-KB-Luciferase Reporter by MUClIA and MUClIB 
TNFa activation ofNF-KB induces IL-l~ and IL-8 transcription. To determine if 
MUClIA and MUClIB affect NF-KB activation, a NF-KB luciferase reporter assay was 
performed in COS-7 cells transfected with EV, MUClIA, MUClIB or MUC1~EX (Fig 
20). As expected, TNFa increased NF-KB luciferase reporter activity in a concentration-
dependent manner in cells treated for 4 or 24 h with TNFa. MUClIB overexpressing 
cells showed reduced TNFa-induced reporter activity when treated with 1 ng/ml TNFa 
for 4 h compared to the EV control. With 10 ng/ml TNFa, both MUClIA and MUClIB 
overexpressing cells showed inhibition of the NF -KB reporter activity compared to EV at 
4 h. Interestingly, MUC1~EX overexpression did not inhibit the NF-KB luciferase 
response, suggesting that the extracellular domain is required to inhibit the NF-KB 
response. When COS-7 cells were incubated with 1 or 10 ng/ml TNFa for 24 h, similar 
responses to the 4 h were observed. MUClIB significantly inhibited 1 and 10 ng/ml 
TNFa- activated NF-KB luciferase activity, whereas MUClIA increased the NF-KB 
luciferase activity at 1 ng/ml but had no effect at 10 ng/ml. These results are in 
agreement with the IL-l~ and IL-8 mRNA expression results showing an inhibition of 
IL-l~ and IL-8 by MUClIB at 4 h. 
Regulation of micro RNA miR-21 by MUClIA and MUClIB 
A recent report showing that IL-l ~ and TNF a induced miR -21 expreSSIOn VIa 
NF-KB activation in pancreatic cancer cells (146) prompted us to examine if MUClIA or 
MUClIB would affect TNFa-induced miR-21 expression. miR-21 is an oncomir and has 
also been shown to be upregulated by ERK activation in cardiac fibroblasts 
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Figure 20. Effect of MUClIA and MUClIB overexpression in TNFa-induced NF-
kB activation. COS-7 cells were transfected with 250 ng of a NF -kB luciferase reporter 
(Promega), 5 ng of a Renilla luciferase reporter (pRL-tk) from Promega and 500 ng 
plasmid DNA for EV, MUCIIA or MUClIB. Forty-eight hours after transfection, wells 
were left untreated (UT) or treated with IoriO ng/ml TNFa. The cells were harvested at 
4 and 24 h after treatment. Luciferase and Renilla luciferase activities were determined. 
Values were calculated as described in Material and Methods and are the mean ± SEM of 
3 experiments. *, p<0.05 compared to EV. **, p<O.OOI compared to EV. #, p<0.05 
compared to MUCIIA. ##, p<O.OOI compared to MUCIIA. 
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(147). Because our data show that MUClIB inhibits TNFa-induced IL-l~ expression at 
4 h, we hypothesized that MUCIIB will abrogate the induction ofmiR-21 by TNFa. The 
results agreed with the predicted outcome: MUCIIB inhibited TNFa-induced miR-21 
expression at 24 h (Fig. 21A). Surprisingly, MUCIIA also inhibited the TNFa-induced 
miR-21 up-regulation, but to a lesser extent than MUCIIB. 
We next examined if the regulation ofmiR-21 by MUCIIA and MUClIB leads to 
changes in genes that are downstream of miR-21. Established gene targets of miR-21 
regulation include programmed cell death 4 (PDCD4) (148). Based on the inhibition of 
miR-21 in cells expressing MUCIIA and MUCIIB, we hypothesized that PDCD4 
inhibition will be blocked in these cells. Figure 21B shows that MUCIIA and MUCIIB 
reduced basal PDCD4 expression and blocked the suppression of PDCD4 detected in 
TNFa-treated cells. The reduction in PDCD4 is commensurate with the increase in miR-
21 seen in TNFa-treated-EV -transfected cells (Fig. 21A). Together, these data indicate 
that both MUCIIA and MUCIIB inhibit TNFa-induced miR-21 expression and thus 
ameliorate the blockade of PDCD4 expression. PDCD4-/- mice show reduced 
inflammatory responses indicating that PDCD4 promotes inflammation (149). The 
ability of MUCIIA and MUClIB to suppress basal PDCD4 expression may inhibit 
inflammation. 
MUCI Ectodomain Release 
The MUCI-N, also called the ectodomain, is shed into the media from human 
comeallimbal epithelial cell line (RCLE) and human uterine epithelial cells (RES) under 
normal conditions as well as in response to specific stimuli including TNFa (139;150). 
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Figure 21. MUClIA and MUClIB inhibit TNFa-induced miR-21 expression. COS-
7 cells transfected with EV, MUClIA or MUCIIB were treated with IOng/rul TNFa for 
24 h. (A) QRT-PCR for mature miR-21 was quantified using 5S rRNA for normalization. 
(B) QRT-PCR for PDCD4 mRNA was normalized to I8S rRNA. Values are the avg. +/-
SEM from triplicate determinations in one experiment. 
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Since MUCIIA and MUCIIB differ in their ability to regulate the induction of 
inflammatory cytokines, MUCIIA and MUCIIB ectodomain release was examined to 
determine if these variants differ in ectodomain shedding. Figure 22 shows the amount 
ofMUCI-N released into the media oftransfected cells, either untreated or treated with 1 
or 10 ng/ml TNFa for 24 h. There was an increase in the amount of MUC1-N released 
into the media from cells expressing MUCIIB and treated with 10 ng/ml TNFa. In 
contrast, MUCIIA expressing cells did not increase the MUCI-N release in response to 
TNFa treatment. There was no significant difference in the amounts of MUCl-N shed 
between cells transfected with MUCIIA or MUCIIB; however, there was a trend for 
higher MUCIIA ectodomain release in cells untreated or treated with 1 ng/ml TNFa. 
Discussion 
We recently reported that MUCIIA and MUCIIB splice variants show different patterns 
of expression in conjunctival tissue from non-Sjogren's and evaporative dry eye 
compared to normal controls (44). The lack of expression of MUCIIA in samples from 
patients with non-Sjogren's dry eye disease indicates a possible protective role of 
MUC1/A in preventing the symptoms accompanying dry eye disease. The biological 
significance of these MUCl splice variants and how they contribute to dry eye 
susceptibility remain to be elucidated. This report demonstrates for the first time that 
MUCIIA and MUCl/B differ in their ability to regulate the TNFa-induced inflammatory 
responses. Whereas MUCIIB was previously reported to have anti-inflammatory activity 
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Figure 22. MUCI ectodomain release in COS-7 cells transfected with MUClIA or 
MUCIIB and treated with TNFa. Conditioned media was collected COS-7 transfected 
with empty vector (EV), MUClIA (A), or MUCIIB (B) grown in 6-well plates and 
treated with the indicated concentrations of TNFa. for 24 h. The media was concentrated 
and identical amounts were separated on 3-8 % Tris-acetate gels. The immunoblots were 
probed with an antibody (DF3) to the extracellular domain of MUCl. To control for 
loading, an identical gel was stained with Coommassie blue. The graph represents the 
quantification of the MUCI-N bands normalized to the Coommassie net pixel intensity of 
the entire lane. Values are the average of 3 separate experiments ± SEM. 
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(65;144), this is the first report to demonstrate that the MUCIIA splice variant has a 
functional role in the regulation of cellular inflammation and that there are specific 
differences in the anti-inflammatory activities of these two splice variants. We observed 
that MUClIB has greater efficacy in inhibiting the pro-inflammatory response induced by 
TNFa compared to MUCIIA. These data indicate that the insertion of 9 aa in the 
MUCI-N terminal domain forming MUCIIA alters the cell signaling properties of 
MUCI. Specifically, we demonstrated that, depending on the experimental conditions, 
MUClIB inhibits the increase in IL-lf3 and IL-S stimulated by TNFa whereas MUCIIA 
increases the expression of these two pro-inflammatory cytokines. Not all cellular 
responses are different between MUCIIA and MUClIB, e.g., both inhibit the induction of 
miR-21 by TNFa and inhibit basal PDCD4 expression. In addition, we demonstrate that 
MUClIA, and not MUClIB, increases basal TGFf3 expression. To the best of our 
knowledge, this is the first report showing that MUCI regulates TGFf3 expression. 
In patients with dry eye disease, the ocular surface is exposed to pro-
inflammatory cytokines produced by infiltrating lymphocytes (151). Here, MUC liB 
expression in COS-7 cells blocked the TNFa-mediated increase in the transcription of 
pro-inflammatory cytokines IL-l f3 and IL-S. These findings are consistent with a report 
showing that MUCI overexpression inhibits activation of Toll-like receptors in cultured 
cells indicating that MUCI has anti-inflammatory properties (144). Interestingly, the 
inhibition of TNFa-induced cytokine expression by MUClIB was time-dependent, i.e., 
IL-S up-regulation by TNFa was inhibited by MUClIB in the first 4 h after TNFa 
treatment, but that inhibition by MUC liB was ablated at 24 h (Fig. IS). In contrast, 
MUCIIA increased IL-lf3 and IL-S mRNA after 24 h ofTNFa treatment. In summary, 
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these data indicate that MUCIIA has less anti-inflammatory activity than MUCIIB. 
These data do not explain the correlation between the lower frequency of MUCIIA 
expression and non-Sjogrens aqueous deficient and evaporative dry eye, but demonstrate 
that MUCIIA and MUCIIB mediate different cytokine responses to TNFa. Interestingly, 
the TNFa-stimulated cytokine response in MUC1L\EX-expressing cells was similar to 
MUCIIB- expressing cells. This result was somewhat unexpected because MUC1L\EX 
lacks most of the extracellular domain which is the part of MUCl that is different 
between MUCIIA and MUCIIB. Thus, the pro-inflammatory phenotype of MUCIIA 
indicates that the extra 9 aa in the N-terminus affects its signaling properties. 
The precise mechanisms accounting for the differential role of MUC 11 A and 
MUCIIB in regulating TNFa-induced IL-lf3 and IL-8 transcription remain to be fully 
elucidated. However, we postulate that differential regulation of the NF -KB pathway by 
MUCIIA and MUCIIB plays a key role in the concomitant differences in cytokine 
expression. We demonstrated that MUCIIB, but not MUCIIA, inhibited TNFa-induced 
NF-KB driven luciferase reporter activity with 24 h TNFa treatment. However, in 
agreement with our data showing that MUCIIA inhibited TNFa-induced IL-8 mRNA 
only at the 4 h time point, MUC II A inhibited TNF a activation of the NF -KB luciferase 
reporter activity only at 10 ng/ml TNFa at 4 h. These findings indicate different time-
dependent effects of MUCIIA versus MUCIIB in response to TNFa. Surprisingly, 
MUClL\EX did not inhibit TNFa-induced activation of the NF-KB driven luciferase 
reporter. These results were unexpected because the MUCl-CD is thought to mediate the 
intracellular activities of MUCl (57) and also because L\EX blocked TNFa-induced 
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induction of IL-I ~ and IL-8. This intriguing finding further supports the idea that 
MUCI-N and MUCI-CD subunits work together to modulate signal transduction events. 
The 9 aa insertion in the MUCI-N did not cause differences in PM localization 
between MUCIIA and MUCIIB; however, there may be subtle differences in their 
localization that were not detected. It is also possible that MUCIIA and MUCI/B 
interact with a different repertoire of regulatory proteins in the PM and cytoplasm or 
other intracellular compartments that differentially mitigate the TNFa-induced 
inflammatory response. Another possibility is that the MUCI-CD of MUClIA and 
MUCIIB are differently phosphorylated which would be expected to differentially impact 
downstream signaling. Although the extra 9 aa in MUCIIA-N are not predicted to create 
or delete a phosphorylation site, it is possible that MUCIIA and MUClIB interact with 
different protein kinases/phosphatases that alter intracellular signaling. 
It is also important to note that COS-7 cells were used in this study because they 
are readily transfectable and MUCI null. However, these monkey kidney cells are not a 
good model for the polarized epithelial cells that constitute the ocular surface. There is 
no cell polarity in COS-7 cells, thus the cellular distribution and PM localization of 
MUCI/A and MUClIB may be different in other cells. Furthermore, COS-7 cells lack 
detectable levels of intracellular signaling targets, i.e., IKBa and IKK (Y. Imbert, 
unpublished observation) making additional studies of signaling pathways impossible in 
this cell line. Future studies should utilize cells more appropriate to dry eye such as 
corneal or conjunctival epithelial cell lines. Nevertheless, the results presented here with 
COS-7 cells clearly indicate functional differences between MUC 11 A and MUC liB. 
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The increase TGF~ basal expressIOn by MUClIA has not been previously 
reported. TGF~ is a potent anti-inflammatory cytokine that plays an important role in 
maintaining the lacrimal gland homeostasis (38). TGF~ ablation in mice leads to the 
development of "crusty eyes" due to inflammation of the lacrimal gland (32). The ability 
of MUClIA to induce TGF~ suggests that one mechanism by which MUClIA confers 
protection to the ocular surface is by providing constitutive protection to the lacrimal 
gland through TGF~. Since the frequency of the MUClIA only genotype was reduced in 
dry eye disease patients (Table 3), this important finding requires further investigation. 
Our data indicate that both MUClIA and MUClIB inhibit TNFa-induced miR-2l 
expression and thus ameliorate the blockade of PDCD4 expression. miRNAs are 
upstream regulators of gene expression and are responsible for controlling important 
physiological and pathological processes, including inflammation (reviewed in (152)). 
PDCD4 is a tumor-suppressor gene that inhibits protein translation and stimulates 
inflammation. TNFa-downregulation of PDCD4 in pro-inflammatory environments was 
reported to decrease inflammation (149; 153). To our knowledge, this is the first 
investigation of the effect of MUCI on miR-2l expression and activity. The ability of 
MUCI/A and MUClIB to increase the levels of PDCD4 in response to TNFa provides 
another mechanism by which these splice variants can sustain inflammation. 
In conclusion, our findings indicate that MUClIA and MUClIB have overlapping 
and distinct anti-inflammatory properties as reflected in cytokine activation and NF-KB 
regulation, but similar activities in regulating miR-2l expression. The difference in the 
function of MUClIA and MUClIB detected in transfected COS-7 cells is the first step in 
understanding how their expression in conjunctival tissue is involved in dry eye disease. 
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CHAPTER VI- RESEARCH IMPLICATIONS 
Dry eye is a complex and multifactorial disease, whose underlying causes are 
unknown (5). Patients suffering from this chronic and debilitating disease can find relief 
from the symptoms with current palliative therapies; however, these therapies do not yet 
stop the progression of the disease. Evidence accumulated over the past few years has 
identified a number of factors that correlate with susceptibility to develop dry eye disease 
including aging, hormonal status, environmental stress, meibomian gland dysfunction, 
mucin status, and autoimmune attack to the secretory glands of the eye. Such 
correlations, however, do not provide a mechanism for the occurrence of dry eye disease. 
This dissertation focused on the role of MUC 1 splice variants as potential genetic factors 
that regulate the mechanisms behind the pathologies associated with dry eye disease. 
Advances in understanding the causative elements of dry eye disease will be beneficial to 
patients currently suffering from this disease. 
One major finding of this dissertation is that MUCIIA expression is reduced in 
the non-Sjogren's and evaporative dry eye population (described in Chapter IV) (44). 
The lower frequency of MUCIIA in the dry eye population establishes MUCIIA and 
MUClIB expression status as genetic susceptibility factors, and suggests a protective role 
of the MUCIIA splice variant against ocular damage that is associated with dry eye 
disease. Elucidating how MUCIIA and MUClIB relate to the cellular and molecular 
elements involved in the occurrence of dry eye disease may lead to the discovery of new 
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therapeutic targets. The experiments described in Chapter V build on results from 
Chapters III and VI and examined the role of MUClIA and MUClIB in regulating the 
cellular inflammatory response. The results from these studies demonstrated for the first 
time that MUClIA and MUClIB differently regulate inflammatory signals. Specifically, 
I present evidence that MUCIIA had mixed pro- and anti-inflammatory activities 
depending on the experimental conditions, whereas MUCIIB had a short-lasting anti-
inflammatory activity after exposure to short-term (4 h) TNFu. 
MUCI is a membrane-anchored mucin expressed at the ocular surface and 
provides protection against extrinsic insults. Consistent with the importance ofMUCl in 
maintaining the integrity of the ocular surface, studies have examined whether MUCI 
levels were altered in the dry eye population compared to controls (16;154). In one study 
MUCI protein and mRNA was found to be increased in Sjogrens's dry eye compared to 
non-Sjogren's and normal controls subjects (154). The same study also detected 
increased soluble MUCI expression in tears of non-Sjogren's aqueous deficient dry eye 
compared to normal controls. However, these changes in MUCI expression are likely a 
consequence or a compensatory response to the chronic inflammatory nature of the 
disease. In contrast, we identified the reduced frequency of the MUClIA splice variant 
as a genetic susceptibility element contributing to the prevalence of non-Sjogren's and 
evaporative dry eye (44). These data indicate that non- Sjogren's and evaporative dry 
eye must share some common underlying mechanisms that involve MUCl. 
The results presented in Chapter VI indicate that the size of the VNTR is not the 
element responsible for providing protection against dry eye. The Southern blot data 
(Fig. 14) demonstrated that, contrary to what I had initially hypothesized, MUClIA 
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alleles do not correlate 100 % with large size VNTR and therefore, the protection that 
comes from expressing MUCIIA alleles is not simply from mechanical hindrance. 
The work presented in Chapter V examined the role of MUCIIA and MUCIIB in 
the regulation of cellular inflammation. One important finding in this Chapter is that the 
expression of the MUCIIA splice variant correlates with an increase in basal levels of 
TGFB (Fig. 19). TGFB plays an anti-inflammatory role in the ocular surface; therefore, 
our data indicates that MUCIIA confers protection to the ocular surface by increasing 
TGFB. It will be interesting to determine if MUCIIA and MUCIlB genotype correlates 
with TGFB expression levels in human subjects. Future research will be necessary to 
determine the mechanism by which MUCIIA increases TGFB expression. 
Another interesting discovery was that MUCIIA stimulated the TNFa-mediated 
proinflammatory response at 24 h (Figs. 18 and 20). Although I had initially 
hypothesized that MUCIIA would have greater anti-inflammatory activity, based on the 
reduced MUCIIA only genotype in dry eye patients, these data remain consistent with the 
hypothesis that MUCIIA plays a protective role. Inflammation is a defense mechanism 
to protect tissues from external damage and therefore it could be advantageous to have 
enhanced expression of pro inflammatory mediators for a short period of time. 
The discovery that MUCI/A and MUCIIB have a differential role m the 
regulation of inflammation is also relevant to tumorigenesis. It is well established that 
inflammation is a critical component of tumor progression (for review (155)) and 
therefore, our findings are also relevant to the development and progression of cancer. 
The expression of MUCI splice variants have been reported in breast, ovarian, cervical, 
and prostate tumors (101; 156-158). The frequency of the MUC 11 A genotype was 
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reported to be significantly reduced in hereditary prostate cancer compared to the 
population (158). Likewise, MUClIA expression has been reported to be reduced in 
ductal carcinoma in situ (159). The functional discrepancies between MUC 11 A and 
MUClIB described here can therefore be used as models to explore the role of MUCl 
splice variants in the development of cancer. 
One strength of this research is that we identified MUClIA and MUClIB as 
genetic elements contributing to the prevalence of two categories of dry eye, and we have 
demonstrated different physiologic functions of these two splice variants in transfected 
COS-7 cells. Importantly, the ability to link specific genetic variations to differences in 
molecular functions that mediate pathogenic events causing the symptoms of dry eye 
disease will provide new targets for potential intervention therapies. One drawback from 
the studies conducted in Chapter V is that COS-7 cells were used because of their ease in 
uptake of plasmids, rather than corneal or conjunctival cells. It is possible that in a 
different cell context, these splice variants may exhibit different properties. Another 
limitation is that much of what we have learned in terms of how MUClIA and MUClIB 
regulate inflammatory responses is based on a model of acute TNFa-stimulated 
inflammation. Therefore, how our results compare to a chronic inflammation setting 
such as in dry eye disease remains to be tested. Despite these limitations, this research 
has provided new knowledge about the importance of MUCl splice variants in dry eye 
disease. Additionally, these studies have opened new avenues for further research. 
Finally, although the MUClIA and MUClIB status alone is not sufficient to cause or to 
predict the development of dry eye, a more direct role of MUC 11 A and MUC liB as 
regulators of important cellular processes such as inflammation has been demonstrated. 
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APPENDIX 1- RESULTS FROM INITIAL AIMS 2 AND 3 
Initial Aim 2: Determine ifMUCl interacts directly and functionally with ERa and/or 
ER~ in human submandibular gland (HSG) and ocular surface epithelial cell lines. 
Here I will describe the experiments done towards completion of this aim. 
Experiment I: Western Blot analysis was performed to determine MUC I, ERa 
and ER~ protein expression in HSG and TERT-immortalized human corneal epithelial 
cell line (hTCE-D, kindly provided by Dr. S.D. Dimitrijevich, University of North 
Texas). Fig. 23A shows MUCl and ERa protein expression in hTCE-D, HSG, and 
MCF-7 cells (MCF-7 were used here as positive controls for MUCl and ERa). a-tubulin 
was used as a loading control. The migration size of ERa appears lower than the 
expected 67 kDa for full length ERa, but we note that migration of the baculovirus-
expressed rhERa and ERa in the NE from MCF-7 cells shows comparable migration. 
Fig. 23B demonstrates that HSG and hTCE-D cells express ER~. These results indicate 
that HSG and hTCE-D cells and are suitable to express MUCl, ERa and ER~ and 
therefore are suitable for the studies proposed in this aim. 
Experiment 2: Coimmunoprecipitation (coIP) experiments were performed using 
H23 and Hl793 non small cell lung cancer cell (NSCLC) lines. Although these 
experiments were not performed in HSG or hTCE-D cells, they provide evidence of 
interaction between MUCl and ERa and ER~. ColP experiments revealed that MUCl 
interacts constitutively with ERa and ER~ in Hl793 and H23 lung adenocarcinoma cells 
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(Fig. 24). The lower interaction of MUC1 and ERa/~ in H23 cells is likely due to low 
levels of MUC 1 in H23 cells compared to H 1793 cells. 
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Figure 23. MUC1, ERa, and ERP are expressed in HSG and hTCE-D cells. Protein 
lysates from the indicated cells were subjected to immunoblotting with anti-MUC1 , anti-
ERa, anti-ER~ and a-tubulin antibodies. Lysates were loaded on a 4-12% Bis-Tris gel 
(Invitrogen). (A) Western blot probed with CT2 anti-MUCI (NeoMarkers) and AER320 
anti-ERa (NeoMarkers). (B) Western blot probed with H150 anti-ER~ (Santa Cruz). 
Baculoviral-expressed recombinant human ERa and ER~ (rhER~ 1, long form) were used 
as positive controls. a- tubulin was used as a loading control. Immunoreactive bands 
were visualized using the Kodak Image Station 440CF. 
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Figure 24. MUCl, ERa and ER~ interact in lung cancer cells. H23 and H1793 lung 
adenocarcinoma cells were grown in 5% CSS-FBS-supplemented medium for 48 h prior 
to treatment. H23 was derived from a male patient and H1793 from a female patient 
(133) . The cells were treated with ethanol vehicle control (EtOH), 10 nM estradiol (E2) 
or 100 nM 4-hydroxytamoxifen (4-0HT) for 1 h. Nuclear fractions were prepared using 
NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce) according to the 
manufacturer's protocol. 400 Ilg nuclear extracts (NE) were immunoprecipitated with 
(A) HC-20 anti-ERa (Santa Cruz) or (B) H-150 anti-ERp (Santa Cruz). The proteins 
were separated on 14% Tris-Glycine gel (Invitrogen) and transferred to PVDF 
membranes. The membranes were probed with CT2 anti-MUCI (NeoMarkers) and (A) 
AER320 anti-ERa (NeoMarkers) or (B) H-150 anti-ERp antibody (SantaCruz). Human 
recombinant ERa/p was used as a control for ERa/p reactivity. 
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Initial Aim 3: Elucidate the anti-inflammatory role of MUCl, ERa and/or ER~ in human 
submandibular gland and human ocular surface. 
Experiment 1: QRT-PCR was performed to examine HSG response to TNFa 
treatment. HSG cells were treated with 10 ng/ml TNFa for 4 h, mRNA levels for the 
indicated genes were determined. TNFa increased transcription of cyc1ooxygen~se 
isoform 2 (COX-2), IL-l~, IL-8 and ICAM-l in HSG cells (Fig. 25). 
Experiment 2: Previous reports have shown that MUCI is upregulated by TNFa 
in a human uterine epithelial cell line (139), hence I examined the expression of MUC 1 
mRNA and protein in response to TNFa treatment in HSG cells. HSG cells were left 
untransfected or transfected with EV, MUClIB, or MUC1~EX and treated with TNFa. 
Figure 26 shows the mRNA and protein levels of MUCI. Here we demonstrate that 
MUCI is upregulated in response to TNFa treatment in HSG cells. 
Experiment 3: To test the potential anti-inflammatory activity of MUClIB in 
HSG cells, cells were transiently transfected with either an empty vector or MUClIB 
using the Amaxa nuc1eofector. After 48 h, the cells were incubated with 10 ng/ml TNFa 
for 4 and 24 h to induce an inflammatory response. As indicated in Fig. 27A, I was able 
to overexpress MUClIB in HSG cells. Fig 27B shows mRNA levels of IL-8 in cells 
transfected either with an EV or with MUClIB that were left untreated or incubated with 
10 ng/ml TNFa for 4 and 24 h. Treatment of HSG cells transfected with an EV with 
TNFa for 4 and 24 h induced IL-8 mRNA expression by 78- and 200- fold, respectively. 
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The increase in IL-8 mRNA expreSSIOn is attenuated in HSG cells overexpressing 
MUClIB. These data agree with the results shown in Chapter V (Fig. 18) and show that 
MUC liB inhibits the TNFa-induced inflammatory response in HSG cells as well as 
COS-7 cells. 
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Figure 25. TN Fa induces transcription of COX-2, IL-1P, IL-8 and ICAM-l in HSG 
cells. HSG cells were treated with 10 ng/ml TNFa for 4 h. A) QRT-PCR shows that the 
fold induction for COX-2, IL-l13, IL-8 and ICAM-l compared to untreated was 5, 3, 23 
and 9 respectively. B) QRT-PCR data for ICAM-l expression. Note that the scale for the 
ICAM-l graph is not identical to panel A. The fold induction for ICAM-l in response to 
TNFa was - 7-fold 
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Figure 26. TNFa treatment increases MUCl expression. HSG cells were left 
untreated or treated with 10 ng/ml TNFa for the indicated times. MUCI mRNA and 
protein levels were analyzed. (A) MUCI QRT-PCR in HSG cells untransfected (UTx) or 
expressing an EV, MUCI /B or MUC1~EX. Cells were treated with 10 ng/ml TNFa for 
4, 24 and 48 h. Shown in the graph is the fold induction compared to untreated cells. (B) 
MUCI protein expression in HSG cells 24 and 48 h after TNFa incubation. Briefly, 
25)lg total protein was separated on 3-8% Tris-Acetate gel (Invitrogen). Proteins were 
transferred to PVDF membranes and probed with the DF3 antibody against MUCI-N 
(Signet). (C) and (D) Immunoreactive MUC 1 bands were quantified using UnScanIt ver. 
6.1 (Silk Scientific). The graphs represent the top band of MUCI normalized to u-
tubulin and compared to the untreated control for each transfected construct. 
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Figure 27. MUClIB overexpression inhibits TNFa-induced IL-8 expression in HSG 
cells. HSG cells were left untransfected or transfected with either no DNA (mock 
control), an empty vector control (EV) or MUClIB. 48 h post-transfection the cells were 
left untreated or treated with 10 ng/ml TNFa for 4 or 24 h. (A) MUCI-CD expression in 
HSG cells 48 h post-transfection. Briefly, 18 Ilg total protein was separated on 12% Bis-
Tris gel (Invitrogen). Proteins were transferred to PVDF membranes and probed with the 
CT2 antibody against MUCI-CD (NeoMarkers). (B) IL-8 QRT-PCR in HSG cells 
expressing either an EV or MUClIB. Cells were treated with 10 ng/ml TNFa for 4 and 
24h. 
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